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ABSTRACT 
Lan Huang 
 
ENDOTHELIAL COLONY FORMING CELLS (ECFCS): IDENTIFICATION, 
SPECIFICATION AND MODULATION IN CARDIOVASCULAR DISEASES 
 
A hierarchy of endothelial colony forming cells (ECFCs) with different levels of 
proliferative potential has been identified in human circulating blood and blood 
vessels. High proliferative potential ECFCs (HPP-ECFCs) display properties 
(robust proliferative potential in vitro and vessel-forming ability in vivo) consistent 
with stem/progenitor cells for the endothelial lineage. Corneal endothelial cells 
(CECs) are different from circulating and resident vascular endothelial cells 
(ECs). Whereas systemic vascular endothelium slowly proliferates throughout life, 
CECs fail to proliferate in situ and merely expand in size to accommodate areas 
of CEC loss due to injury or senescence. However, we have identified an entire 
hierarchy of ECFC resident in bovine CECs. Thus, this study provides a new 
conceptual framework for defining corneal endothelial progenitor cell potential. 
The identification of persistent corneal HPP-ECFCs in adult subjects might 
contribute to regenerative medicine in corneal transplantation. While human cord 
blood derived ECFCs are able to form vessels in vivo, it is unknown whether they 
are committed to an arterial or venous fate. We have demonstrated that human 
cord blood derived ECFCs heterogeneously express gene transcripts normally 
restricted to arterial or venous endothelium. They can be induced to display an 
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arterial gene expression pattern after vascular endothelial growth factor 165 
(VEGF165) or Notch ligand Dll1 (Delta1
ext-IgG) stimulation in vitro. However, the in 
vitro Dll1 primed ECFCs fail to display significant skewing toward arterial EC 
phenotype and function in vivo upon implantation, suggesting that in vitro priming 
is not sufficient for in vivo specification. Future studies will determine whether 
ECFCs are amenable to specification in vivo by altering the properties of the 
implantation microenvironment. There is emerging evidence suggesting that the 
concentration of circulating ECFCs is closely related to the adverse progression 
of cardiovascular disorders. In a pig model of acute myocardial ischemia (AMI), 
we have demonstrated that AMI rapidly mobilizes ECFCs into the circulation, with 
a significant shift toward HPP-ECFCs. The exact role of the mobilized HPP-
ECFCs in homing and participation in repair of the ischemic tissue remains 
unknown. In summary, these studies contribute to an improved understanding of 
ECFCs and suggest several possible therapeutic applications of ECFCs.  
  
 
 
Mervin C. Yoder, Jr., MD, Chair 
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CHAPTER I 
Introduction 
A. The Formation of Functional Blood Vessels 
Blood vessels deliver oxygen and nutrients while removing waste from all tissues 
in the body. The vascular system is hierarchically organized and is composed of 
functional arteries, capillaries and veins. Capillaries are composed solely of 
endothelial cells (ECs), and occasionally are ensheathed with pericytes. Arteries 
and veins have an inner layer of ECs and an outer layer of vessel wall, which 
consists of the tunica intima, media and adventitia. The formation of blood 
vessels is an elaborate process including vasculogenesis, angiogenesis, 
arteriogenesis, vascular remodeling and maturation, all of which involves a wide 
variety of biochemical and biomechanical factors (Figure I.1).  
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Figure I.1 Formation of a functional vascular network from endothelial 
precursor cells during murine embryonic development. Mesoderm-derived 
angioblasts and hemangioblasts give rise to the primitive capillary plexus in the 
yolk sac via vasculogenesis before circulation is established. Subsequently, the 
primary capillary plexus quickly expands and undergoes further remodeling. 
Angioblasts also migrate into the embryo and directly aggregate into dorsal 
aorta and cardinal vein via vasculogensis and angiogensis. These primary 
vessels later connect to the primary capillary plexus in the yolk sac and form 
functional vasculature that carries blood.   
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Vasculogenesis and Regulation  
The development of the vascular system is one of the earliest events in 
embryogenesis. Gastrulation begins at embryonic day (E) 6.5, as evidenced by 
the formation of the primitive streak and leads to the formation of three principle 
germ layers: the ectoderm, mesoderm and endoderm (Wells & Melton 1999). 
The emergence of endothelial cells (ECs) is first observed in the proximal lateral 
mesoderm of the extraembryonic yolk sac. The subpopulation of mesoderm cells 
that expresses vascular endothelial growth factor receptor 2 (VEGFR2, also 
known as kinase insert domain receptor, KDR in humans; or fetal liver kinase 1 
Flk-1 in mice) gives rise to both angioblasts (endothelial progenitors) and 
hemangioblastic cells (progenitors of both hematopoietic and endothelial 
lineages) in the yolk sac (Drake & Fleming 2000, Kabrun et al 1997, Kataoka et 
al 1997, Nishikawa 1997). During the migration of these mesodermal cells, the 
primary capillary plexus (the earliest blood vessels) begin to form by angioblasts 
as a honeycomb-like network that separates the distal embryo proper from the 
proximal blood island region (Ferkowicz & Yoder 2005). At the same time, the 
earliest hematopoietic progenitor cells (primitive erythrocytes) first appear near 
the primitive streak and migrate past the developing primitive capillary plexus into 
the blood island region of the proximal yolk sac, where they rapidly divide and 
form a circumferential blood cell band at E7.75. The primitive erythrocytes in this 
region are not surrounded by ECs initially. However, a sheet of ECs exists on the 
visceral endodermal side of the blood band. ECs appear to invade the blood 
band, subdividing it into primitive erythrocyte-filled channels that eventually form 
4 
 
a blood-filled vascular bed, which connects to the primitive capillary plexus right 
before the onset of circulation around E8.25 (Ferkowicz et al 2003, Ferkowicz & 
Yoder 2005). Extraembryonic EC differentiation initially occurs without 
concomitant hematopoiesis. Primitive blood vessels are formed de novo by the 
patterned assembly of angioblasts in a process termed vasculogenesis (Risau & 
Flamme 1995).  
 
Vasculogenesis in the embryo proper appears slightly later and is initiated 
around E7-7.5 by mesoderm fated to give rise to the endocardium and cranial 
regions (Drake & Fleming 2000, Tam & Behringer 1997). Subsequently, primary 
vascular networks appear serially, lateral to the midline, as the paired dorsal 
aortae, then the head and cardinal vessels (Argraves & Drake 2005, Flamme et 
al 1997, Lawson et al 2002). Later, neovascularization of heart, lung, liver, spleen 
and kidney occurs also primarily by vasculogenesis (Aird 2007a, Aird 2007b, 
Coultas et al 2005, deMello et al 1997, Ferguson et al 2005, Robert et al 1998). 
In addition, allantoic vasculogenesis occurs by the assembly of mesoderm-
derived precursor cells (Downs et al 1998, Drake & Fleming 2000), giving rise to 
the umbilical vessels (Downs & Harmann 1997). Intraembryonic EC 
differentiation, similar to that in the yolk sac, initiates in the absence of 
hematopoiesis.  
 
After the onset of circulation, the primary vascular networks are rapidly expanded 
and remodeled into arteries, capillaries and veins; ultimately, a functional 
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circulatory loop is established. As development proceeds, the primitive 
erythrocytes in circulation are replaced by definitive hematopoietic cells 
(Brotherton et al 1979, McGrath & Palis 2005, Steiner & Vogel 1973). Thus, 
vasculogenesis collectively results in the formation of the primary capillary plexus 
in the yolk sac and the major embryonic vessels.  
 
Mouse knockout studies have identified many genes that contribute to 
vasculogenesis (Argraves & Drake 2005). While several signaling pathways 
participate into this process, including FGF signaling (Poole et al 2001, Smith 
1989), Wnt signaling (Wang & Wynshaw-Boris 2004, Zerlin et al 2008), BMP 
signaling (Winnier et al 1995) TGFβ signaling (Sirard et al 1998, Yang et al 1998) 
and Indian hedgehog signaling (Dyer et al 2001), none of these signaling 
cascades is specific for developing the endothelial lineage.  
 
In sharp contrast, Flk-1 plays a vital role in differentiating mesoderm exclusively 
to endothelial and hematopoietic lineages in the early gastrulating embryo 
(Dumont et al 1995, Roman & Weinstein 2000). Flk-1 deficiency (Flk-1-/-) 
severely impairs the development of ECs and hematopoietic cells, and causes 
embryonic death at E8.5 (Shalaby et al 1995). Similarly, vascular endothelial 
growth factor (VEGF, Flk-1 ligand) is indispensable for vasculogenesis. Targeted 
deletion of VEGF leads to embryonic lethality. VEGF-/- embryos display a 
phenotype similar to that observed in Flk-1 knockout mice, but considerably less 
severe (Carmeliet et al 1996, Ferrara et al 1996). Interestingly, further studies 
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demonstrate that VEGF is haploid-insufficient — loss of a single VEGF allele is 
lethal in the mouse embryo, causing abnormal blood vessel development. This 
indicates a tight dose-dependent regulation of embryonic vessel development by 
VEGF.  
 
Vascular endothelial growth factor receptor 1 (VEGFR1 or FMS-like tyrosine 
kinase 1, Flt-1) is another VEGF receptor and is also primarily expressed in ECs. 
Flt-1 knockout mice exhibit normal EC differentiation but abnormal vascular 
organization in early embryogenesis (Fong et al 1995, Fong et al 1999). Flt-1 has 
a higher affinity for VEGF binding but lower kinase activity compared to Flk-1. 
Thus, Flt-1 might serve in part to modulate Flk-1 activity by sequestering excess 
VEGF stimulation.  
 
Angiogenesis and Regulation  
Once the basic pattern of primitive extraembryonic and intraembryonic 
vasculature is formed by vasculogenesis, blood vessels are expanded and 
remodeled rapidly. This process, referred to angiogenesis, is defined as the 
expansion of blood vessels from preexisting vessels. Angiogenesis involves 
many morphological events including sprouting EC growth, intussuseptive 
growth, stabilization, remodeling, pruning and specialization (Carmeliet 2000, 
Flamme et al 1997, Jain 2003, Patan 2004, Risau & Flamme 1995).  
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Sprouting angiognesis happens in many regions such as the yolk sac, central 
nervous system (CNS) and retina (Breier & Risau 1996, Gerhardt et al 2003, 
Kurz et al 1996, Noguera-Troise et al 2006, Ridgway et al 2006). Angiogenic 
sprouting is characterized by leading tip cells and trailing stalk cells (Gerhardt et 
al 2003). This process could be prompted by an insufficient supply of oxygen and 
guided by VEGF via Notch signaling (comprehensively reviewed in Gerhardt 
2008 and Phng 2009) (Gerhardt 2008, Phng & Gerhardt 2009). Hypoxia 
upregulates VEGF expression and activates nitric oxide synthase (NOS) which 
leads to the bulk production of nitric oxide (NO) (Fraisl et al 2009). Existing 
vessels then dilate in response to NO and become leaky in response to VEGF. 
With the involvement of active proteases, the basement membrane and 
extracellular matrix (ECM) are degraded. These events make ECs acquire 
invasive and migratory ability. 
 
ECs stimulated by VEGF compete for the tip cell position via Dll4/Notch1 
signaling. The cell that produces more Dll4 than its neighbors eventually will 
remain as a tip cell because it can sufficiently suppress the same response in 
adjacent ECs via activated Notch1 signaling (Phng & Gerhardt 2009). VEGF also 
induces the expression of its receptor Flk-1 and the formation of long, dynamic 
filopodia in the tip cells. Thus, tip cells are able to migrate along VEGF gradients. 
The VEGF gradient on EC surface is tightly regulated by mRNA levels, isoform 
splicing, cell membrane retention and probably protein degradation. A spatial 
concentration gradient of membrane-bound VEGF (VEGF188 and VEGF164 in 
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mice, and VEGF189 and VEGF165 in humans) functions as a chemoattractant 
signal that promotes the polarized extension of tip cells. In contrast, diffused 
VEGF (VEGF120 in mice; VEGF121 in humans) promotes EC proliferation but 
does not guide tip cells (Gerhardt 2008). 
 
While sprouting, the vascular lumen can form by ECs in the absence of mural 
cells. Lumenization requires the coordinated participation of multiple molecules 
including small GTPases and cell-cell, cell-matrix adhesion proteins (Avraamides 
et al 2008, Dejana et al 2009, Horowitz & Simons 2008, Iruela-Arispe & Davis 
2009, Koh et al 2008). Furthermore, growing vascular sprouts can generate 
gradients of platelet-derived growth factor B (PDGFB), which promote the 
recruitment of pericytes via PDGFB receptor β (PDGFR β). This ensures that the 
growing endothelium is efficiently stabilized by mural cells, which enable ECs to 
withstand the physical forces of blood flow (Gerhardt et al 2003). 
 
Each new spout ultimately needs to suppress its motile behavior and connect 
with adjacent sprouts or existing capillaries. Flow-dependent tissue oxygenation 
downregulates paracrine VEGF production and thus helps establish a quiescent 
state for these new vessels. The investment of mural cells and the deposition of 
ECM proteins into the subendothelial basement further contribute to vessel 
quiescence and maturation (Jain 2003, Jones et al 2006, Lucitti et al 2007). The 
basement membrane provides critical support for the endothelium and 
fundamentally affects its status, mainly through adhesive interaction with 
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integrins on the surface of ECs. For example, laminin-binding integrins such as 
α3β1 and α6β1, as well as collagen IV and perlecan, are important for regulating 
tube stabilization and EC quiescence (Davis & Senger 2005, Iruela-Arispe & 
Davis 2009, Stratman et al 2009). Moreover, plasmin and Matrix 
metalloproteinases (MMPs) (such as MMP3) are reported to be able to release 
VEGF165 from the ECM by converting it into a soluble isoform VEGF121-like 
component and sequester VEGF165 signaling, restoring EC quiescence 
(Mancuso et al 2006). Furthermore, vascular architecture specializes according 
to local tissue and organ growth, such as the formation of heart valves and 
fenestration. Lastly, arteries and veins form and expand, acquiring additional 
layers of mural cells, ECM and elastic laminae coverage, giving the vessels full 
ability to sense pressure and respond accordingly.  
 
Cumulative evidence indicates that many elements are capable of influencing 
angiogenesis, including oxygen, metabolic intermediates, blood flow, cytokines 
and growth factors (Adams & Alitalo 2007, Fraisl et al 2009, Jain 2003, Larrivee 
et al 2009). The principal player in angiogenesis is VEGF, which promotes EC 
sprouting, proliferation, migration, differentiation and survival, and controls EC-
EC, EC-ECM interactions and more. Many other molecules such as fibroblast 
growth factor (FGF), Angiopoietin/Tie2, Notch, TGFβ/Alk5, S1P/Edg1, 
Ephrin/Eph and integrins also participate in regulating angiogenic responses. 
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VEGF and VEGF receptors 
The VEGF family belongs to the platelet-derived growth factor (PDGF)/VEGF 
supergene family. At least 7 members comprise this family: VEGF-A, VEGF-B, 
VEGF-C, VEGF-D, VEGF-E, placental growth factor (PlGF) and snake venom-
derived VEGFs. NOTE: In this chapter, ―VEGF‖ stands for VEGF-A. Binding of 
VEGF to KDR is the main extracellular signal triggering angiogenic responses, 
for example, regulating EC proliferation and NO generation. KDR efficiently 
activates phospholipase Cγ (PLCγ), which cleaves phosphatidylinositol-4, 5-
bisphosphate (PtdIns(4,5)P2) to produce diacylglycerol (DAG) and inositol-
trisphosphate (IP3). These soluble products release calcium from the 
endoplasmic reticulum (ER) and activate protein kinase C (PKC). The latter 
activates MRK-MAPK pathway which affects DNA synthesis in ECs (Takahashi 
et al 1999, Xia et al 1996). In addition, VEGF increases eNOS activity through a 
pathway mediated by Src and thus produces NO. Calcium release also helps the 
production of NO. Thereafter, VEGF via NO affects EC division, migration and 
apoptosis (Donnini & Ziche 2002, He et al 1999). Moreover, VEGF via activated 
Notch signaling can regulate many steps of angiogenesis, of which endothelial 
sprouting and arterial-venous specification have been investigated at length 
(Ahmed & Bicknell 2009, Coultas et al 2005, Gerhardt 2008, Holderfield & 
Hughes 2008, Roca & Adams 2007, Siekmann et al 2008).  
 
VEGF can interact with both VEGF receptors Flt-1 and Flk-1. Flt-1 has weak 
tyrosine kinase activity and high affinity for VEGF, which makes it act as a decoy 
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receptor, modulating angiogenesis through its ability to sequester VEGF and 
thereby reduce signaling through Flk-1 (Park et al 1994). Consistently, deletion of 
Flt-1 gene in the embryo or embryonic stem-cell-derived vessels induces 
overgrowth of endothelial cells and vessel dysmorphogenesis (Fong et al 1995, 
Fong et al 1999). By contrast, mice that express a membrane-anchored Flt-1 
variant lacking a tyrosine-kinase domain (Flt-1TK-/-) but still capable of binding 
VEGF are basically healthy and do not exhibit vascular defects (Hiratsuka et al 
1998). It is of interest that the Flt-1 gene also encodes a secreted soluble protein 
that has only one ligand-binding region, called soluble Flt-1 (sFlt-1) (Kendall & 
Thomas 1993, Shibuya et al 1990). sFlt-1 level was reported to be abnormally 
elevated in the serum of preeclampsia patients. Recent studies indicate that 
abnormal trapping of VEGF with excess sFlt-1 causes hypertension and 
proteinuria, which are the major symptoms of preeclampsia (Koga et al 2003, 
Maynard et al 2003). Similarly, overexpression of sFlt-1 induces over-proliferation 
of glomerular ECs with the loss of endothelial fenestration (a hallmark of the 
glomerular vascular endothelium) that resembles the renal histological lesions of 
preeclampsia (Baumwell & Karumanchi 2007). Moreover, sFlt-1 has recently 
been indicated to play an important role in angiogenic sprouting (Chappell et al 
2009, Kappas et al 2008).Spatially regulated expression of sFlt-1 in conjunction 
with VEGF contributes to the formation of spatial VEGF gradient and therefore 
guides emerging sprouts away from parent vessels. Thus, Flt-1 regulates 
vascular development by sequestering excess VEGF and contributes to maintain 
vascular homeostasis. 
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Flt4 is expressed mainly in lymphatic ECs and through response to VEGF-C and 
VEGF-D regulating lymphangiogensis. However, Flt4 also plays an important role 
in VEGF signaling in angiogenesis (Dumont et al 1993), likely by forming a 
heterodimer with KDR (Dixelius et al 2003). Flt4 abundant expression has been 
observed in zebrafish intersegmental vessels (ISV), at the tip cells of ISVs in 
mouse embryos and in the front of sprouts in mouse retinas (Gerhardt et al 2003, 
Siekmann & Lawson 2007). Interestingly, loss of Notch signaling increases Flt4 
expression in stalk cells, while suppression of Flt4 expression partly restores the 
sprouting, indicating that Flt4 is downregulated by Notch activity in stalk cells. 
However, one in vitro study suggested activated Notch signaling can upregulate 
Flt4 (Shawber et al 2007). Therefore, the underlying mechanism needs to be 
clarified.  
 
Neuropilins (Nrps) including Nrp1 and Nrp2 play an important role in both 
neuronal and blood vessel development. They are receptors for two types of 
ligands, the class 3 semaphorin (SEMA) family of axon guidance molecules and 
the VEGF family of angiogenic factors. Nrp1 is primarily expressed in arteries 
while Nrp2 is abundant in veins and lymphatic vessels (Herzog et al 2001, Yuan 
et al 2002). The first evidence of Nrp1’s involvement in angiogenesis was that 
overexpression of Nrp1 in transgenic mice resulted in embryonic lethality and 
vascular defects; for example, excess numbers of blood vessels and 
hemorrhage. (Kitsukawa et al 1995). Nrp1-deficient mice exhibit abnormal 
vascular development, including impaired neural vascularization and 
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disorganized, insufficient development of vascular networks in the yolk sac and 
the mice die in utero (Kawasaki et al 1999). However, Nrp2-deficient mice are 
viable; they develop arteries and veins normally but fail to develop small-
diameter lymphatic vessels and capillaries (Yuan et al 2002). In addition, 
Nrp1/Nrp2 double-knockout mice display more severe vascular defects than 
Nrp1-deficient mice and die at E8.5 (Takashima et al 2002). Recent studies 
indicate that Nrp signaling can be independent of VEGF/KDR, by binding Nrp 
interacting proteins (NIPs) such as RGS-GAIP Interacting Protein (GIPC) and 
Synectin (Cai & Reed 1999, Chittenden et al 2006, Gao et al 2000). Collectively, 
the roles of Nrps in angiogenesis need to be clarified in greater depth. 
 
Angiopoietins and Tie receptors  
The angiopoietin family is composed of four ligands (Angiopoietin1, 
Angiopoietin2 and Angiopoietin3/4) and two corresponding tyrosine kinase 
receptors (Tie1 and Tie2). Ang3 and Ang4 are orthologs found in mice and 
humans, respectively. Tie receptors are specifically expressed in the endothelium 
(Thomas & Augustin 2009, Yancopoulos et al 1998). Tie2 is the receptor for all 
four angiopoietin ligands, but the ligand for Tie1 is not clear yet. It recently has 
been shown that Tie1 can interact with Tie2 to form a heteromerized signaling 
complex (Saharinen et al 2005). Tie1-deficient mice either die in utero (Puri et al 
1995) or perinatally (Sato & Rifkin 1989) with edema and hemorrhage, which 
indicates Tie1 is associated with angiogenesis. 
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Ang1 is expressed mainly in mural cells (Ramsauer & D'Amore 2002), but Ang2 
is produced and stored in ECs (Eklund & Olsen 2006, Fiedler et al 2006). The 
Ang1/Tie2- dependent signaling cascade has been demonstrated to promote 
angiogenesis, stabilize nascent vessels via recruitment of pericytes, reduce 
vascular permeability and exhibit anti-inflammatory activity (Armulik et al 2005, 
Eklund & Olsen 2006, Koblizek et al 1998, Thurston et al 1999). Mice embryos 
lacking Tie2 and Ang1 initially develop a rather normal vascular network, but it 
fails to be further remolded, which is similar to mice in which Ang2 is 
overepxressed in the endothelium (Dumont et al 1994, Maisonpierre et al 1997, 
Sato et al 1995, Suri et al 1996). This observation indicates that Ang2 may 
counteract Ang1 signaling. Further studies reveal that the role of Ang2 is 
contextual. In the absence of VEGF, Ang2 destabilizes vessels and contributes 
to vascular regression; but in the presence of VEGF, Ang2 becomes angiogenic 
and facilitates vascular sprouting (Eklund & Olsen 2006, Maisonpierre et al 
1997). 
 
FGF and FGF receptors 
The FGF family members are heparin-binding protein mitogens that play critical 
roles in diverse biological processes (Itoh 2007). This family is composed of 22 
FGF ligands and four tyrosine kinase receptors (Eswarakumar et al 2005). While 
FGFs promote a strong angiogenic response, FGF-induced angiogenesis 
appears to require activation of VEGF signaling (Presta et al 2005). Several lines 
of evidence suggest that FGF regulates both VEGF and KDR expression in ECs. 
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However, once VEGF signaling is activated, its ability to induce angiogenesis 
appears to be independent of FGF signaling (Murakami & Simons 2008). 
Moreover, mice that are null in FGFR1, FGFR2, FGFR3, FGFR4, FGF1, FGF2 
and FGF1/FGF2 don’t exhibit abnormal vascular defects (Arman et al 1998, 
Deng et al 1994, Miller et al 2000, Ortega et al 1998, Weinstein et al 1998, 
Yamaguchi et al 1994, Zhou et al 1998). These findings imply extensive 
redundancy of FGFs and leave their distinct role in vascular development 
unclear.  
 
PDGF and PDGF receptors 
PDGFs and their receptors (PDGFRs) have long served as prototypes for growth 
factor and receptor tyrosine kinase function. The PDGF family consists of 
PDGFA, PDGFB, PDGFC and PDGFD, encoded by genes PDGF-A and PDGF-
B (Heldin & Westermark 1999). PDGF receptors contain PDGFRα and PDGFRβ. 
PDGFRβ is expressed in microvascular ECs in vitro and contributes to EC 
proliferation, sprouting and lumen formation (Bar et al 1989, Battegay et al 1994). 
Moreover, the expression of PDGFRβ in pericyes and vascular smooth muscle 
cells (vSMCs) is very critical for mural cell proliferation, guided migration and 
incorporation into the vessel wall. The expression of PDGFB in nascent vessels 
favors recruitment of mural cells that expressing PDGFRβ (Armulik et al 2005, 
Betsholtz et al 2005). 
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PDGFRβ function may involve cooperation with a family of G-protein coupled 
receptors that bind to sphingosine-1-phosphate (S1P), called S1P receptors 
(S1PR1-5) (Allende & Proia 2002, Spiegel & Milstien 2003). S1PR1-deficient 
mice exhibit a phenotype similar to that of PDGFB- and PDGFRβ-knockout mice, 
where mural cells fail to migrate to blood vessels (Kono et al 2004). S1PR1 is 
expressed mainly in ECs and involves trafficking of N-cadherin to the endothelial-
mural-cell contact region (Allende et al 2003, Paik et al 2004). Endothelial N-
cadherin is important for the expression of adhesion molecules, embryonic 
survival and cardiovascular development (Resink et al 2009). Therefore, PDGFB-
PDGFRβ signaling affects vascular homeostasis.  
 
Oxygen regulation 
Oxygen tension can determine whether blood vessels maintain quiescence or 
undergo angiogenesis. A major link between hypoxia and angiogenesis is the 
upregulation of hypoxia-inducible factor (HIF), which plays a central role in the 
transcriptional activation of angiogenic factors. HIFs are heterodimeric 
transcriptional factors consisting of α and β subunits. While HIF1β is insensitive 
to oxygen, HIF1α and HIF2α are oxygen-sensitive and are rapidly degraded by 
catalytic hydroxylation of prolyl hydroxylase domain-containing proteins (PHDs). 
In general, HIF1α is expressed ubiquitously (Semenza 2003), but HIF2α is 
expressed primarily in the endothelium. During hypoxia, HIFs can induce gene 
expression via direct binding to hypoxia response elements (HRE) on gene 
promoters. These genes include VEGF (Forsythe et al 1996), Flt-1 (Gerber et al 
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1997, Takeda et al 2004), erythropoietin (EPO) (Morita et al 2003, Semenza & 
Wang 1992), and eNOS (Coulet et al 2003). Also, many genes not known to 
contain HRE still can be activated by HIF, such as FGF2, PlGF, PDGFB, Ang1, 
Ang2 and Tie2. Hypoxia induces VEGF expression in ECs and pervascular cells 
and regulates EC functions via autocrine and paracrine VEGF signaling. It is very 
interesting to note that intracellular VEGF/KDR signaling plays an important role 
in maintaining EC viability and vascular integrity, which is supported by the 
observation that EC-specific deletion of VEGF leads to EC apoptosis and loss of 
vascular integrity (Lee et al 2007). 
 
Genetic modification experiments have revealed the distinct roles of HIFs in 
vascular development. HIF1β knockout mice display deficient angiogenesis in the 
yolk sac, which is embryonically lethal (Maltepe et al 1997). HIF1α-deficient mice 
exhibit severe vascular defects (Carmeliet et al 1998, Ryan et al 1998) that 
cannot be rescued by HIF2α. This indicates the functions of HIF1α and HIF2α 
are distinct, rather than overlapping. On the other hand, overexpression of HIF1α 
promotes revascularization, improving perfusion in ischemic tissues in rabbit 
models with hindlimb ischemia (Vincent et al 2000). Targeted deletion of HIF2α 
also causes many vascular abnormalities, according to different genetic 
backgrounds (Compernolle et al 2002, Duan et al 2005, Scortegagna et al 2003). 
Moreover, the lack of both HIF1α and HIF2α leads to impaired vascular 
remodeling and failure of vascular sprouting in the embryo and yolk sac (Licht et 
al 2006). In addition, HIF2α is uniquely able to induce the expression of eNOS 
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and VE-Cad, which affects vascular remodeling and maturation (Coulet et al 
2003, Le Bras et al 2007). 
 
Theoretically, PHD activity could regulate angiogenesis. PHD2-null embryos die 
in utero but do not display increased angiogenesis, although HIF1α and HIF2α 
levels are elevated significantly (Aragones et al 2008, Takeda et al 2007). One 
possible explanation is that angiogenesis in the developing embryo is intact 
during this time window and excess HIF-α accumulation has a relatively 
insignificant impact. In contrast, PHD2 deficiency in adult mice results in 
significantly increased angiogenesis (Haase et al 2001, Rankin et al 2005, 
Takeda et al 2007). Furthermore, PHD1- and PHD3-knockout embryos are 
apparently normal, which might be due to compensation by PHD2, because the 
latter is the most abundantly expressed PHD isoform. Therefore, PHDs are 
important for maintaining vascular integrity in the adult. Collectively, the 
regulation of angiogensis by oxygen tension is a complex process involving 
numerous molecular mechanisms and requires further in-depth investigation. 
 
Integrins  
The ECM serves as a storehouse for various growth factors and proenzymes that 
regulate angiogenesis. ECs adhere to the ECM through the expression of 
surface-bound integrins. Integrins have 18 unique α and 8 unique β subunits and 
at least 24 distinct α/β integrin heterodimers have been identified. Integrins 
interact with many basement membrane components, such as fibronectin (FN), 
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vitronectin, collagen, laminin and heparin-sulfate proteoglycans, to form focal 
adhesion complexes and thus regulate EC proliferation, migration, adhesion and 
survival (Cheresh & Stupack 2008).  
 
The proteolysis of many basement membrane proteins produces many 
antiangiogenetic fragments including angiostatin, endostatin, kininostatin, 
endorepellin ,restin, tumstatin and vastatin (Chen et al 2006, Jimenez et al 2000, 
John et al 2005, O'Reilly et al 1997) and the molecular mechanisms by which 
they function are yet unknown. It is likely that many as yet uncharacterized 
fragments remain to be discovered. Endorepellin, a C-terminal proteolytic 
fragment of perlecan, is one example of our incomplete knowledge of its 
functionality (Bix et al 2004). Endorepellin binds to integrin α2β1 (a collagen 
receptor), resulting in EC actin cytoskeleton disassembly and focal contact 
disruption, causing migration failure and aborted tube formation. Interestingly, 
endorepellin also can bind to endostain and counteract its antiangiogenetic 
activity. In addition, many of these proteolytic fragments require circulating forms 
of plasma FN and vitronectin for their antiangiogenic activites (Akerman et al 
2005). Thus, the precise roles of the interaction between integrins and basement 
membrane in angiogenic regulation need further investigation.  
 
Intussusceptive Angiogenesis (IA) and Regulation 
Non-sprouting angiogenesis or IA is a process in which transvascular tissue 
pillars form within capillaries, small arteries, and veins and subsequently fuse. 
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This results in the formation of vascular trees (intussusceptive arborization) or 
vessel remodeling (intussusceptive branching remodeling) (Burri et al 2004, 
Makanya et al 2009). It was first observed in developing pulmonary vessels 
(Patan et al 1993) and later was found in other organs and tissues such as the 
heart and yolk sac during embryonic development. IA’s direct influence on 
structural remodeling optimizes vessel formation and function in the local organ 
(Kurz et al 2003). Although hemodynamic forces such as increased blood flow 
have been demonstrated to directly influence IA to initiate pillar formation, the 
underlying molecular mechanism is still unclear. Moreover, little is known about 
the molecular regulation of IA. 
 
Arteriogenesis and Regulation 
As discussed already, sprouting angiogenesis leads to an increase in capillary 
vessel density and improves blood perfusion of hypoxic tissue. Thus, sprouting 
angiogenesis is necessary to maintain or restore local oxygen and nutrition 
supplies and prevent vessel stenosis. However, this process may not be 
sufficient to restore the function of larger arteries (Scholz et al 2002). In contrast, 
arteriogenesis—defined as the growth of functional collateral arteries from 
preexisting arterio-arteriolar anastomoses (Schaper & Schaper 1997)—partially 
contributes to the rescue of artery function. Arteriogenesis is initiated by altered 
fluid shear stress (FSS) caused by a blood flow change due to an arterial 
occlusion and is independent of hypoxia (Deindl et al 2001, Ito et al 1997).  
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Numerous studies in experimental animal models with hindlimb ischemia indicate 
arteriogenesis is a complicated process that relies on the interaction of FSS, 
growth factors and cytokines, proteolytic enzymes and local inflammation. 
Arteriogenesis can be divided roughly into four phases (Schaper 2009). The first 
phase follows an initial artery occlusion. During this phase, quiescent ECs and 
vascular smooth muscle cells (vSMCs) become proliferative and vascular 
permeability is increased. The second phase is characterized by destruction of 
the collateral artery by degradation of the basement membrane, internal elastic 
lamina and collagen, accompanied by a burst of proliferation in ECs and vSMCs. 
Thereafter, the maturation phase proceeds and can be described as the orderly 
arrangement of vSMCs in multiple layers, the synthesis of elastin and collagen to 
generate new extracellular scaffolds, and the reestablishment of cell-cell and cell-
matrix association. At the last phase, pruning and remodeling occur; only a few 
large vessels continue to grow, while great numbers of small vessels regress by 
the competition for blood flow. 
 
Although arteriogenesis has been well illustrated, its precise underlying 
molecular mechanisms remain elusive and need further investigation. ECs sense 
changes in FSS, which leads to activation of eNOS. Then eNOS generates NO, 
which induces VEGF expression. Upregulated VEGF in ECs stimulates 
Monocyte chemoattractant protein-1(MCP-1) expression in vSMCs, which 
triggers activation, migration and adhesion of monocytes to the endothelium. 
After monocytes mature into macrophages, these cells produce additional 
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cytokines (such as FGF and TNFα) that contribute to vSMC proliferation. They 
also produce proteases (such as MMPs), which help digest the basement 
membrane. Consequently, vSMCs lose their tight cell-cell and cell-matrix 
connections, allowing vessels to enlarge (Cai et al 2000). Moreover, the 
interaction between PDGFB (expressed by ECs) and PDGFRβ (present on 
vSMCs) contributes to the migration and recruitment of vSMCs to ECs where 
they form the neointima layer (Hellstrom et al 1999). Additionally, vSMCs are 
involved in reconstitution of elastin lamina and the tunica media. The active 
status of vSMCs is finally shut down when vessel maturation is complete (Scholz 
et al 2000). 
 
Besides monocytes, T cells and NK cells recently were reported to be involved in 
arteriogenesis; but their roles are unclear (Heil & Schaper 2004, Stabile et al 
2003, van Weel et al 2007). Bone marrow-derived cells also have been 
described to be recruited to the growing collateral artery, but they do not 
incorporate into the vessel wall (Kinnaird et al 2004, Ziegelhoeffer et al 2004). 
This suggests that paracrine signaling of cytokines or growth factors produced by 
these cells contributes to arteriogenesis. This makes bone marrow-derived cells 
and growth factors as interesting targets for clinical therapeutics (van Oostrom et 
al 2008). 
 
In summary, arteriogenesis is potentially able to preserve the function of an 
occluded artery. The success of this remodeling process depends on close 
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coordination of a variety of mechanical and biochemical factors as discussed. 
Complete understanding of the molecular machinery for arteriogenesis is still 
elusive. 
 
B. Arteriovenous (AV) Differentiation 
During the early stage of embryogenesis, arteries and veins in the primary 
capillary plexus form via a process known as AV differentiation (Adams & Alitalo 
2007, Jain 2003, Torres-Vazquez et al 2003). Growth and specification of 
arteries and veins continues throughout development and reflects distinct 
hemodynamic properties within the vascular architecture. Formerly it was 
believed that AV differentiation of ECs in the primary capillary plexus was due to 
the influence of hemodynamic forces (Dewey et al 1981). In 1998, Wang was the 
first to find that EphrinB2 and EphB4 are markers for arterial and venous ECs, 
respectively, in the primary capillary plexus (Wang et al 1998). This suggested 
that arterial and venous EC determination is at least partially governed by genetic 
factors prior to the establishment of circulation. Since then, numerous molecules 
and signaling pathways have been described that participate in AV differentiation 
(Table I.1 and Figure I.2). For example, arterial ECs express high levels of 
Notch1 and 4 (Villa et al 2001), Jagged1 and 2 (Villa et al 2001), Delta-like ligand 
4 (Dll4) (Shutter et al 2000), Ephrin B2 (Wang et al 1998), Neuropilin 1 (Nrp1) 
(Mukouyama et al 2002) and Hey2 (Chi et al 2003); whereas venous ECs are 
characterized predominately by the expression of EphB4 (Wang et al 1998), Nrp-
2 (Herzog et al 2001, Yuan et al 2002) and COUP-TFII (You et al 2005).  
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Arterial gene Species 
ALDHIA1 Human (Chi et al 2003) 
Alk1  Mouse (Seki et al 2003) 
CD44  Mouse (Fischer et al 2004), human (Chi et al 2003) 
Connexin37  Mouse (Shin & Anderson 2005) 
Connexin40  Mouse (Mukouyama et al 2002, van Kempen & Jongsma 1999) 
CXCR4  Mouse (Ara et al 2005) 
deltaC  Zebrafish (Smithers et al 2000) 
Delta-like 4 Mouse (Shutter et al 2000) 
Depp  Mouse (Shin & Anderson 2005) 
EphrinB2 Zebrafish (Lawson et al 2001), chick (Moyon et al 2001, Othman-Hassan et al 2001), mouse 
(Adams et al 1999, Wang et al 1998) 
EVA1 Human (Chi et al 2003) 
Foxc  Mouse, Human (Seo et al 2006) 
Gridlock/Hey2 Zebrafish(Zhong et al 2000), human (Chi et al 2003) 
IGFBP-5P  Mouse (Shin & Anderson 2005) 
ITM2A Human (Chi et al 2003) 
Jagged1 Mouse (Villa et al 2001) 
Jagged2 Mouse (Villa et al 2001) 
KRT7 Human (Chi et al 2003) 
LIPG Lipase Human (Chi et al 2003) 
Neuropilin-1 chick (Herzog et al 2001, Moyon et al 2001), Mouse(Mukouyama et al 2002), 
Notch1 Mouse (Villa et al 2001) 
Notch4 Mouse(Villa et al 2001), human (Chi et al 2003) 
Notch5  Zebrafish (Lawson et al 2001) 
Sox Zebrafish (Sakamoto et al 2007) 
Tbx20  Zebrafish (Ahn et al 2000) 
Unc5b Mouse (Lu et al 2004) 
 
Venous gene Species 
APJ  Mouse (Devic et al 1999) 
COUP--TFII Mouse (You et al 2005) 
EphB4 Zebrafish (Lawson et al 2001), mouse (Adams et al 1999, Wang et al 1998), Xenopus (Helbling 
et al 2000), human (Chi et al 2003) 
Flt4 Zebrafish (Thompson et al 1998), mouse (Kaipainen et al 1995) 
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GDF1 Human (Chi et al 2003) 
Lefty1/2 Human (Chi et al 2003) 
Myosin 1B Human (Chi et al 2003) 
Neuropilin-2 Chick (Herzog et al 2001), Mouse (Yuan et al 2002) 
smootherned  Human (Chi et al 2003) 
Tie2 Chick (Moyon et al 2001) 
Table I.1: Molecules expressed preferentially in arterial and venous ECs 
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Figure I.2 Model of AV specification. VEGF interacts with the Flk-1-Nrp1 
complex to activate downstream Plc-γ-Erk and Notch signaling pathways, thus 
inducing expression of arterial gene markers Hey2 and EphrinB2, while 
inhibiting expression of venous gene EphB4. Foxc proteins also activate the 
Notch pathway, leading to an arterial identity. Activated Notch can suppress 
COUP-TFII expression, thereby repressing a venous fate. Conversely, COUP-
TFII can inhibit Nrp1 expression and thus attenuate VEGF signaling and 
downstream Notch activation. Moreover, the PI3K-AKT cascade represses Erk 
signaling. Therefore, a venous fate is promoted. Unconfirmed interactions are 
indicated by dashed arrows. The molecules and signaling pathways that favor 
an arterial fate are shown in black, while those that promote a venous fate are 
in grey. 
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Regulation of AV Specification 
Ehprin/Eph  
The first genes that were found to be expressed differentially in arterial and 
venous endothelium were Ephrin B2 and EphB4 (Adams et al 1999, Wang et al 
1998), which are members of the Eph receptor tyrosine kinases (RTK) - Ephrin 
family. The ligand Ephrins are divided into 2 subclasses: the A-subclass 
(EphrinA1-A6), which anchored to the cell surface via a 
glycosylphosphatidylinositol (GPI); and the B-subclass (EphrinB1-B3), which has 
a transmembrane domain, followed by a short cytoplasmic region. Similarly, the 
Eph receptors are divided into A and B subclass (EphA1-A8 and EphB1-B6, 
respectively). The interactions of Ephrins and Ephs are prominent and are not 
class restricted (Klein 2004, Kullander & Klein 2002). Because Ephrins and Ephs 
are both membrane-bound, Ephrin-Eph signaling requires cell-cell contact. A 
unique feature of Ephrins is that they are capable of receptor-like active 
signaling. This results in bidirectional signal transduction, where conserved 
tyrosine residues in the approximately 85aa long cytoplasmic domain of Ephrin 
ligand are phosphorylated and recruit signaling effectors (Bruckner et al 1997, 
Holland et al 1996).  
 
The distinct expression pattern of arterial EphrinB2 and venous EphB4 was first 
discovered in mice in the primary capillary plexus before initiation of circulation 
(Adams et al 1999, Gerety et al 1999, Wang et al 1998). Since then, it has been 
confirmed in chicks and zebrafish (Lawson et al 2001, Lawson et al 2002, Moyon 
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et al 2001, Othman-Hassan et al 2001, Zhong et al 2001). More importantly, the 
interaction of EphinB2 with EphB4 is critical for proper vascular development. In 
knockout mice lacking EphrinB2, the primary capillary plexus forms, but its 
remodeling into a hierarchical, organized vasculature is arrested (Adams et al 
1999, Wang et al 1998). Moreover, the dorsal aorta forms in these animals, while 
the cardinal vein remains a loose, nonfunctional network of ECs (Adams et al 
1999). These two vessels initially are formed by vasculogeneis. Similar 
phenotypes are present in EphB4-deficient mice (Gerety et al 1999). Thus, 
EphrinB2 and EphB4 are not acquired for determining EC fate during 
vasculogenesis, but they are required to define and maintain the arterial and 
venous interface. Mice lacking the EphrinB2 cytoplasmic domain exhibit defects 
in vascular remodeling similar to those in mice that are completely deficient for 
EphrinB2 or EphB4. This suggests that their bidirectional signaling is also 
important for proper AV specification (Adams et al 2001).  
 
Although EphrinB2 and EphB4 are markers of arteries and veins, studies in 
zebrafish and mice have demonstrated some other critically important upstream 
transcription factors that help determine arterial-venous EC fate, as discussed on 
the following pages.  
 
Notch  
The Notch signaling pathway is an evolutionarily conserved pathway that is 
involved in a variety of developmental processes. Notch family members and 
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Notch ligands are expressed throughout early vascular development and later 
are restricted to arteries (see Table I.1). Mice with targeted deletion of Notch 
molecules including Notch1 (Huppert et al 2000, Krebs et al 2000, Limbourg et al 
2005), Notch4 (Carlson et al 2005, Krebs et al 2000, Uyttendaele et al 2001), 
Jagged1 (Xue et al 1999), Dll4 (Duarte et al 2004, Gale et al 2004, Krebs et al 
2004), Rbpj (Krebs et al 2004), Hey1 and Hey2 (Fischer et al 2004, Kokubo et al 
2005) display severely impaired vascular remodeling in the yolk sac and in the 
embryo proper, which indicates the essential roles of Notch molecules in 
vascular development. In particular, the role of Notch molecules in arterial 
specification has been extensively demonstrated in mice and zebrafish embryos, 
and in human ECs (Gridley 2007, Roca & Adams 2007, Rossant & Hirashima 
2003, Rossant & Howard 2002, Shawber & Kitajewski 2004, Siekmann & Lawson 
2007).  
 
Although Notch4 knockout mice do not exhibit any apparent deficiencies in 
vessel formation, targeted deletion of Notch1 inhibits proper remodeling and 
embryos die in utero. Moreover, Notch1/Notch4 double-knockout mice display 
abnormal vascular development that is even more severe than that seen in 
Notch1 knockout mice (Krebs et al 2000), suggesting that Notch1 and Notch4 
functions partially overlap. Dll4, a ligand of Notch1 and Notch4, is haploid-
sufficient — loss of a single Dll4 allele results in reduced EphrinB2 expression 
and increased EphB4 expression, along with a failure in arterial differentiation 
(Duarte et al 2004). This defect is similar to that observed in Rbpj- and 
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Hey1/Hey2-knockout animals (Fischer et al 2004, Kokubo et al 2005, Krebs et al 
2004). Most recently, Dll1 has been established as a requirement for maintaining 
arterial identity during fetal development and a mediator of postnatal 
arteriogenesis in mice with hindlimb ischemia (Limbourg et al 2007, Sorensen et 
al 2009). Collectively, these findings indicate Notch activity is important for 
promoting an arterial EC fate in mice.  
 
Disruption of Notch signaling in zebrafish has many similar consequences as in 
mice. Mindbomb (mib) in zebrafish encodes a RING ubiquitin ligase that 
promotes ubiquitylation and internalization of Delta. The disruption of Notch 
signaling in mib mutant leads to reduced expression of arterial markers EphrinB2 
and Notch5 and increases expression of venous marker Flt4 in the dorsal aorta. 
Similarly, overexpression of activated Notch5 in the posterior cardinal vein 
causes a decrease in Flt4 expression. The expression of Notch’s downstream 
target gridlock (grl), a zebrafish orthologue of mammalian Hey2, is restricted to 
the dorsal aorta. Knockdown of grl represses Ephrin B2 expression and leads to 
an expansion of adjacent veins. Conversely, overexpression of grl suppresses 
venous growth with loss of Flt4 expression but does not affect dorsal aorta 
formation (Zhong et al 2001, Zhong et al 2000). Although grl is needed for arterial 
differentiation, its expression is not reduced in mib mutations or embryos injected 
with Su(H) (dominant negative suppressor of Hairless), suggesting grl might not 
be a direct target of Notch, making the role of grl in arterial specification in 
zebrafish obscure.  
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VEGF 
VEGF is one of the most potent and ubiquitous vascular growth factors that 
affects many aspects of EC biology (Coultas et al 2005, Rossant & Hirashima 
2003, Rossant & Howard 2002, Ruhrberg 2003). Consistent with VEGF’s 
promotion of arterial EC differentiation in zebrafish, mice embryonic angioblasts 
treated with either VEGF120 or VEGF164 can induce an arterial EC expression 
pattern and undergo arterial specification (Mukouyama et al 2002). Similarly, 
overexpression of VEGF164 in cardiomyocytes in transgenic mice results in an 
increase of EphrinB2+ vessels (Visconti et al 2002). Interestingly, VEGF signaling 
in the regulation of arterial differentiation in mice is in an isoform-sensitive 
manner. Loss of VEGF164 impairs retinal arterial endothelial outgrowth, whereas 
ablation of VEGF164 and VEGF188 perturbs renal arteriogenesis (Mattot et al 
2002, Stalmans et al 2002). 
 
Furthermore, recent work in zebrafish has shown Plc-γ/Erk under VEGF 
signaling favors an arterial EC specification. A molecular cascade (VEGF  Plc-
γ  Pkc  Raf  Mek  Erk) has been identified for promoting an arterial fate 
of ECs (Lawson et al 2003). In contrast, constitutive activation of PI3K/AKT 
induces venous EC fate, while repressing Erk activation (Hong et al 2006). 
Inactivation of AKT with flavone GS4898 reverses PI3K inhibitory effect on Plc-
γ/Erk and thus promotes arterial EC specification (Hong et al 2006).  
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Sonic hedgehog (Shh)  
The Hedgehog (Hh) family is composed of three ligands: sonic hedgehog, indian 
hedgehog and desert hedgehog. They all signal through the same receptors 
called PTCH1 and 2. The Hh signaling functions broadly in vascular development 
including coronary vascular development (Lavine et al 2008, Lavine et al 2006) 
and arterial specification (Lawson et al 2001). In zebrafish, loss of Shh activity 
either in the null mutant embryo sonic-you (syu) or in the embryo that treated with 
Shh signaling inhibitor cyclopamine results in loss of arterial identity and gain of 
venous maker expression (Lawson et al 2002). Conversely, overexpression of 
Shh leads to a switch from venous to arterial identity in posterior vein (Lawson et 
al 2002). In addition, regulation of arterial specification by Shh is critically 
associated with VEGF in the somite (Pola et al 2001). Microinjection of VEGF 
mRNA in Shh-deficient embryos can rescue arterial differentiation. However, 
injection of VEGF mRNA does not promote arterial differentiation in Notch-
deficient embryos. Instead, activation of the Notch pathway in the absence of 
VEGF signaling can induce artery-specific gene expression (Lawson et al 2002). 
Together, these findings indicate that VEGF acts downstream of Shh and 
upstream of the Notch pathway to determine arterial EC fate. 
 
Forkhead box c (Foxc) 
The highly conserved Forkhead box (Fox) proteins are important in 
cardiovascular development (Kume et al 2001). Recent studies demonstrated 
that two Fox family members, Foxc1 and Foxc2, are essential for arterial 
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specification. Foxc1/Foxc2-null mice exhibit a fusion of the dorsal aorta with the 
posterior cardinal vein. In addition, these mutants lack induction of the 
expression of arterial markers including Notch1, Notch4, Dll4, Jagged1, Hey2 
and EphrinB2; whereas, venous markers such as COUP-TFII and EphB4 are 
expressed normally, suggesting that mutant ECs fail to acquire an arterial fate 
(Seo et al 2006). Overexpression of Foxc genes in vitro consistently induces 
expression of arterial markers. The promoters of Dll4 and Hey2 are directly 
bound to and activated by Foxc proteins via a Foxc-binding site (Hayashi & 
Kume 2008, Seo et al 2006). Moreover, activation of Dll4 and Hey2 occurs to a 
greater extent when VEGF acts in combination with either Foxc1 or Foxc2. 
Additionally, the transcriptional activity of Foxc proteins in Dll4 and Hey2 
induction can be further modulated by VEGF-activated PI3K and ERK signaling 
pathways, making the regulation of AV specification via Foxc proteins more 
complicated. Collectively, Foxc transcriptional factors interact with VEGF and 
Notch signaling to regulate arterial gene expression. 
 
Sry-related HMG box (Sox) 
Transcription factors of the Sox family, such as Sox7 and Sox18, are highly 
expressed in developing vasculature and have recently been identified to be 
involved in AV differentiation in zebrafish (Herpers et al 2008, Sakamoto et al 
2007). Although disruption of either Sox protein does not cause any visible 
vascular defects, simultaneous blockage of Sox7 and Sox18 leads to severe AV 
malformation, characterized by vessel fusion and loss of circulation in the 
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posterior part of embryos (Herpers et al 2008). Further examination reveals that 
arterial specification of ECs is severely interrupted in double-knockdown 
embryos, which is often accompanied by failure of arteries to segregate from 
veins. Therefore, Sox7 and Sox18 are dispensable for vascular development 
individually, but synergistically they promote the specification of arterial ECs. 
 
COUP- transcription factor 2 (COUP-TFII) 
COUP-TFII, a member of the orphan nuclear receptor family, has been identified 
as the first regulator that positively mediates venous EC identity (You et al 2005). 
Targeted disruption of COUP-TFII results in embryonic lethality and displays a 
phenotype opposite of that observed in the loss of Notch activity: a partial loss of 
venous identity with reduced (but not completely abolished) EphB4 expression, 
accompanied by ectopic expression of arterial gene markers such as Notch1 and 
EphrinB2. Conditional lack of COUP-TFII in the endothelium causes veins to 
acquire an arterial identity. In contrast, ectopic expression of COUP-TFII in the 
endothelium results in AV malformation, which phenocopies the vascular 
deficiency observed in Nrp1- and Notch1-knockout mice. Moreover, 
overexpression of COUP-TFII represses the expression of Nrp1 and other 
arterial gene markers. It is now known that COUP-TFII suppresses Nrp1 
expression by binding to the Nrp1 promoter. Thus, COUP-TFII is a critical factor 
that regulates the determination of venous EC fate. 
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Plasticity of AV Differentiation 
Although it is now clear that the acquisition of arterial and venous identity is 
determined genetically, there is no doubt that epigenetic factors such as oxygen 
tension, blood flow and the vessel wall’s microenvironment also can influence 
this process. Plasticity of ECs has been observed in the developing embryo by 
performing quail-chick grafting experiments (Moyon et al 2001, Othman-Hassan 
et al 2001). The quail arterial or venous vessel fragments, together with their 
vessel wall from various stages of embryonic development, were grafted into 
developing chick hosts. Quail ECs from arteries and veins were able to populate 
both host arteries and veins with equal efficiency, and the arterial marker 
expression changed with respect to the novel environment, regardless of its 
origin. However, this EC plasticity diminished progressively after E11 (Moyon et 
al 2001). Interestingly, removal of the vessel wall from the aorta, carotid artery 
and vena cava in E14 quail can fully restore the capacity of ECs to colonize to 
host arteries and veins, irrespective of their origin (Moyon et al 2001, Othman-
Hassan et al 2001). These results suggest that specification of arterial and 
venous fate is, to some extent, reversible and the vessel wall may help stabilize 
the arterial and venous choice of ECs. How the vessel wall precisely affects 
endothelial AV determination is yet unknown.  
 
EC plasticity with respect to AV differentiation also occurs during development 
according to blood flow. It is observed that initiation of arterial and venous marker 
expression in the primary capillary plexus occurs independently of flow (le Noble 
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et al 2004, Wang et al 1998). Shortly after the onset of circulation, the vitelline 
artery forms from the arterial capillary plexus in the posterior pole of the embryo 
by fusion of individual capillaries. But not all capillaries are involved in the 
formation of the artery. Some of them become disconnected, exhibit 
downregulation of arterial markers, and then serve to form the vitelline vein (le 
Noble et al 2004). Furthermore, ligation of the vitelline artery on one side of the 
yolk sac makes it become venularized over 24 hours, as judged by the direction 
of blood flow and the expression of arterial makers. Similarly, flow manipulation 
can switch veins to arteries (le Noble et al 2004). Therefore, hemodynamic forces 
also can alter EC AV identity.  
 
Oxygen tension differs in arteries and veins, and this can be another potential 
instructive signal for AV differentiation. The influence of altered oxygen tension 
on AV differentiation has been observed in the developing mouse retinal 
vasculature (Claxton & Fruttiger 2005).  
 
ECs in adults possess limited plasticity for AV differentiation, which has been 
demonstrated in vein graft adaptation in humans and aged rats (Kudo et al 
2007). EphB4 expression was lost and intima-media thickening was observed, 
but arterial markers EphrinB2 and Dll4 were not strongly induced during vein 
graft adaptation to the arterial environments (Kudo et al 2007). 
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Taken together, recent studies have demonstrated that AV specification is 
genetically predetermined, and many molecules involved in the regulation of this 
process have been identified. In addition, environmental factors such as oxygen 
tension, hemodynamic forces and the microenvironment of vessel walls can 
further influence vascular identity in terms of forming and maintaining arteries 
and veins.  
 
C. Endothelial Colony Forming Cells (ECFCs) 
The concept that circulating bone-marrow-derived endothelial progenitor cells 
(EPCs) could contribute to neovascularization via postnatal vasculogenesis was 
first proposed in 1997 (Asahara et al 1997). Since then, EPCs have been studied 
widely and regarded as a mechanism for maintenance of vascular homeostasis. 
Defective regulation of EPCs leads to pathogenesis of various disorders. 
However, to date, no cell surface molecules that uniquely identify EPCs have 
been reported in human or other vertebrate species. This effort continues, as 
researchers seek to isolate and define EPCs based on in vitro adhesion and 
growth, and cell surface phenotype selection using fluorescent-labeled antibodies 
and flow cytometry (see Figure I.3) (reviewed in (Hirschi et al 2008, Yoder & 
Ingram 2009, Yoder et al 2007)).  
 
In the ―cell adhesion and growth‖ approach, low-density mononuclear cells from 
human peripheral blood are isolated and plated on fibronectin- and gelatin-
coated dishes. After several days in culture, nonadherent cells are removed. The 
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adherent cells display the ability to ingest acetylated low-density lipoprotein 
(AcLDL) and bind to fluorescently labeled Ulex europaeus agglutinin I (UEA I) 
plant lectin and thus are deemed as EPCs. These putative EPCs are released 
from culture and undergo staining to confirm expression of endothelial markers 
such as von Willebrand factor (vWF), VE-Cadherin and KDR by flow cytometry. 
In additions, an inverse relationship between the circulating concentration of 
these EPCs and an increased risk for developing coronary artery disease in 
human subjects has been reported (Vasa et al 2001). However, others have 
shown that putative EPCs isolated in this method may also express, to varying 
degrees, CD45, CD11b, CD11c, CD14, CD68, eNOS, and E-selectin, and ingest 
India ink like macrophages do (Rehman et al 2003, Rohde et al 2007, Rohde et 
al 2006, Zhang et al 2006). Actually, the use of fibronectin- and gelatin-coated 
tissue culture plates has been recognized as a method to isolate human blood 
monocytes for differentiation into macrophages (Freundlich & Avdalovic 1983). 
Moreover, monocytes/macrophages are well known to express ―endothelial-
specific‖ proteins, particularly when cultured in conditions that promote 
endothelial growth. Therefore, the use of this method for isolating EPC is not 
reliable. 
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Figure I.3 Common methods of “EPC” culture. Culture of CFU-Hill cells 
includes a 5-day process where nonadherent peripheral blood MNCs plated on 
FN-coated dishes give rise to colonies. ECFCs are derived from adherent 
peripheral blood or cord blood MNCs cultured for 6 to 21 days on rat-tail collagen 
I coated dishes, and colonies display cobblestone morphology. When adherent 
peripheral blood MNCs cultured in FN-coated dishes, they typically do not display 
colony formation. These cells are able to ingest AcLDL and bind to UEA I lectin. 
The other method is to sort CD34+AC133+KDR+ cells directly from peripheral 
blood MNCs instead of plating them. 
 
40 
 
A second method utilizes fluorescent-labeled antibodies and flow cytometry 
analysis to enumerate putative EPC concentrations in human circulation. In the 
first EPC paper, Asahara (Asahara et al 1997) reasoned that putative circulating 
EPCs may express surface molecules shared by endothelial and hematopoietic 
stem/progenitor cells because these two lineages share a similar mesoderm 
origin during early embryogenesis. Thus, human circulating CD34+ cells were 
isolated. They reportedly adhered to fibronectin-coated plates with greater 
frequency than to type 1 collagen-coated plates and displayed a spindle-shaped 
morphology. The adherent putative EPCs expressed a variety of cell surface 
markers that normally were present in human umbilical vein endothelial cells 
(HUVECs). Further studies demonstrated that these putative EPCs (CD34+ or 
KDR+) home to areas of neovascularization when injected in vivo into 
immunodeficient mice with induced hindlimb ischemia. These studies collectively 
indicated that CD34+ or KDR+ circulating cells in human peripheral blood may be 
EPCs and can contribute to postnatal angiogensis. 
 
The number of endothelial cells circulating in the bloodstream in healthy subjects 
is very low, but can increase under certain conditions (Blann et al 2005). Peichev 
(Peichev et al 2000) attempted to define a panel of cell-surface antigens that may 
distinguish EPCs from circulating endothelial cells (CECs). Peichev utilized 
CD34, KDR, and AC133 as EPC markers. AC133, originally identified on 
neuroepithelial cells, is a 5-transmembrane domain cell-surface glycoprotein that 
is expressed in epithelial, hematopoietic, and various cancer stem cells (Mizrak 
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et al 2008). Peichev rationalized that the expression of CD34, KDR and AC133 
should be present in EPCs and the expression of AC133 and CD34 would be 
downregulated in CECs, which is similar to gene expression observed in 
hematopoietic stem cells as they differentiate into more mature progenitors. 
Reportedly, a CD34+KDR+AC133+ population can be identified in adult 
peripheral blood, umbilical cord blood, and human fetal liver samples; but the 
concentration is very low. Subsequently, multiple combinations of CD34, AC133 
and/or KDR have been used extensively to identify circulating EPCs in human 
subjects (reviewed by (Timmermans et al 2009)); and the concentration of 
circulating EPCs has been correlated with many human diseases (Bertolini et al 
2006, Jujo et al 2008, Pompilio et al 2009). However, recent studies have been 
demonstrated that cells expressing CD34, AC133 and/or KDR are enriched for 
hematopoietic colony-forming cells and do not form endothelial cells in vitro and 
in invo (Case et al 2007, Timmermans et al 2007). Thus, the expression of CD34, 
AC133 and KDR in human circulating cells fails to specifically identify a 
circulating EPC. 
 
The third approach utilizes in vitro colony-forming assays to identify putative 
EPCs. Human peripheral blood mononuclear cells are placed on fibronectin-
coated dishes for 48 hours; then the nonadherent cells are replated to quantify 
the emergence of the EPC colony forming units several days later. The putative 
EPCs (that give rise to progeny forming the colony) have been referred to as 
colony forming unit-Hill (CFU-Hill). The CFU-Hill assay has been used to 
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demonstrate a significant inverse correlation between the concentration of 
circulating CFU-Hill and Framingham cardiovascular risk scores in human 
subjects (Hill et al 2003). CFU-Hill has been recognized as being composed of 
an aggregate of round cells overlying adherent spindle-shaped cells expressing 
many proteins similar to the primary endothelial cells. However, these adherent 
spindle-shaped cells also express several myeloid progenitor cell markers and 
mature into macrophages that can readily ingest bacteria. In addition, these cells 
neither proliferate extensively to give rise to secondary colonies in vitro nor form 
blood vessels spontaneously when implanted in vivo in collagen gels (they do not 
display postnatal vasculogenic activity) (Yoder et al 2007). Furthermore, recent 
studies have demonstrated that CFU-Hill cells are mainly T cells and monocytes 
admixed with B cells and natural killer (NK) cells. The combination of purified T 
cells with monocytes is able to form CFU-Hill colonies (Rohde et al 2007, Rohde 
et al 2006). Thus, the CFU-Hill assay identifies hematopoietic cells instead of 
endothelial cells. 
 
We and others have isolated ECFCs from human peripheral blood and cord 
blood (Au et al 2008a, Ingram et al 2004, Melero-Martin et al 2007). Human 
blood low-density mononuclear cells are placed on rat-tail collagen I coated 
dishes, and the nonadherent cells are removed. Several days later, ECFC 
colonies with the typical cobblestone morphology emerge in a medium that 
benefits endothelial cell growth. ECFCs express cell surface proteins (KDR, 
CD34, vWF, eNOS, VE-cadherin, and others) similar to those on primary ECs, 
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but ECFCs do not express hematopoietic cell markers such as CD45, AC133, 
CD11b and CD14 (Ingram et al 2004, Yoder et al 2007). They can proliferate at a 
clonal plating level and replate into secondary and tertiary ECFCs (Ingram et al 
2004). They are able to incorporate AcLDL and form capillary-like structures in 
vitro (Ingram et al 2004). Most importantly, in sharp contrast to CFU-Hill and any 
other putative EPCs, ECFCs are capable of forming human blood vessels in vivo 
in immunodeficient mice and incorporate with murine vasculature to become part 
of murine systemic circulation (Yoder et al 2007). Thus, only ECFCs display all 
the property of EPCs.  
 
In summary, the types of cells being considered as EPCs vary widely from study 
to study, causing controversies in this field. However, the strictest definition of an 
EPC is a circulating cell that 1) displays the ability to produce endothelial progeny 
that form endothelial tubes in vitro and 2) contribute to the functional endothelial 
lining of injured vascular structure via angiogenesis and/or vasculogenesis in 
vivo. Thus, to date, only human ECFCs fit the definition of true EPCs and display 
all the activities described on these pages. 
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CHAPTER II 
A Hierarchy of Endothelial Colony Forming Cell (ECFC) Activity is 
Displayed by Bovine Corneal Endothelial Cells (BCECs) 
Introduction 
Corneal endothelial cells (ECs) are derived from neural crest precursors during 
embryonic development. These unique cells form a distinctive monolayer of 
hexagonally packed cells attached to their specialized basement membrane, 
Descemet’s membrane, and form the most posterior portion of the cornea. 
Corneal ECs fail to proliferate in vivo in response to injury, disease, or aging and 
are arrested in the G1 phase of the cell cycle. However, corneal ECs possess 
replicative potential that can be revealed upon in vitro endothelial cell culture 
and/or application of a stress such as mechanical wounding or ethylene diamine 
tetraacetic acid (EDTA) treatment to disrupt cell-cell interactions within the 
endothelial monolayer on the cornea. A number of laboratories have also 
reported successful growth of untransformed corneal ECs in vitro. Using in vitro 
culture approaches, recent studies demonstrate that the proliferation of corneal 
ECs varies with the age of the donor (cells derived from younger donors divide 
more than those from older donors) and varies from the central cornea (low 
proliferative potential) to peripheral cornea (high proliferative potential). To date, 
it remains unclear if each corneal EC displays proliferative potential in vitro or if 
the replicative ability resides in only a subset of the cells.  
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We have reported on development of methods to examine clonal proliferative 
behavior of circulating and vascular endothelial cells and have identified a 
hierarchy of endothelial colony forming cell (ECFC) activity ranging from high 
proliferative potential ECFC (HPP-ECFC) to non-dividing mature ECs (Ingram et 
al 2005b, Ingram et al 2004). Human umbilical cord blood is enriched in 
circulating ECFCs and the distribution of ECFCs is skewed to a high percentage 
of HPP-ECFCs compared to human adult peripheral blood samples (Ingram et al 
2004). Both cord blood and adult peripheral blood ECFCs display phenotypical 
and functional properties which are also present in ECs derived from human 
blood vessels (Ingram et al 2005b). Furthermore circulating or resident ECFCs 
form human blood vessels de novo when subcutaneously implanted into 
immunodeficient mice and these vessels participate in carrying blood as a part of 
the host murine systemic circulation (Au et al 2008a, Schechner et al 2000, 
Yoder et al 2007). These current studies suggest that ECFCs represent 
stem/progenitor cells for the endothelial lineage.  
 
We questioned whether corneal ECs, although derived from neural crest rather 
than mesoderm and differing in anatomic position, exposure to blood flow and 
blood constituents, and displaying unique physiological functions, displayed 
clonal ECFC potential. We report that BCECs display a complete hierarchy of 
ECFCs that is similar to the distribution of ECFC activity in ECs isolated from 
bovine aorta, coronary artery, and pulmonary artery. HPP-ECFCs in corneal 
endothelium can be replated into at least secondary colonies and retain high 
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levels of telomerase activity similar to HPP-ECFCs derived from resident 
endothelium in blood vessels. These data suggest that the fundamental 
paradigm for endothelial cell lineage development and maintenance may be 
similar in corneal ECs as with other vascular ECs, but the mechanisms for EC 
repair and regeneration are regulated by dominant tissue specific requirements 
and niches.
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Materials and Methods 
Isolation of bovine peripheral blood mononuclear cells (MNCs)  
Blood (50-100ml) was collected from a local slaughterhouse and diluted one to 
one with Dulbecco's Phosphate-Buffered Saline (DPBS) (1X) without Ca or Mg 
(Invitrogen, Grand Island, NY)/1% bovine serum albumin (BSA)/ethylenediamine 
tetraacetic acid (EDTA) solution and layered (2:1 ratio) onto Histopaque1119 
(Sigma-Aldrich, St Louis, MO). Cells were centrifuged for 30 minutes at 1800 rpm 
at room temperature (Beckman Coulter, Fullerton, CA). Low density mononuclear 
cells (MNCs) were isolated as the floating monolayer and washed three times 
with DPBS. Finally, MNCs were resuspended in DPBS with 2% fetal bovine 
serum (FBS) (Hyclone, Logan, UT) for direct analysis by fluorescence activated 
cell sorting (FACS).  
 
Culture of bovine vessel derived endothelial cells (ECs)  
Bovine aortic endothelial cells (BAECs), bovine coronary arterial endothelial cells 
(BCAECs) and bovine pulmonary arterial endothelial cells (BPAECs) were 
purchased from Lonza (Lonza, Walkersville, MD). These bovine vascular 
endothelial cells were plated onto type I rat tail collagen (50 µg/ml) (BD 
Biosciences, Bedford MA) pre-coated tissue culture flasks and cultured in 
endothelial cell growth medium EGM-MV (Lonza) supplemented with 1.5% 
antibiotic-antimycotic (Invitrogen) at 37°C, 5% CO2 in a humidified incubator.  
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Isolation and culture of bovine corneal ECs 
The isolation of bovine corneal endothelial cells (BCECs) was performed as 
previously described (Bonanno and Giasson, 1992). These corneal ECs were 
plated in tissue culture flasks filled with DMEM supplemented with 5% FBS and 
1.5% antibiotic-antimycotic. Corneal ECs were grown to a confluent monolayer 
and the cells displayed a typical hexagonal appearance. These ECs were 
released from the culture dish by using TryPLE (Gibco, Grand Island, NY) and 
re-plated onto 75 cm2 tissue culture flasks for further passage in the 
supplemented DMEM. 
 
Immunophenotyping of endothelial cells 
Early passage (2-4) bovine vascular ECs and corneal ECs as well as bovine 
blood MNCs were stained with a mouse monoclonal antibody against bovine 
CD45 conjugated to fluorescein isothiocyanate (FITC) (SEROTEC, UK), FITC 
conjugated Lycopersicon Esculentum (Tomato) lectin (LEL) and Griffonia 
simplicifolia I lectin (GSL I) (Vector Laboratories, Burlingame, CA) or mouse 
isotype control antibody for 30 minutes at 4°C, washed three times, and analyzed 
for cell surface expression using a FACS Calibur flow cytometer (Becton 
Dickinson, San Diego, CA) as previously described (Huang et al 2007). 
 
Ingestion of 488-conjugated acetylated-low density lipoprotein (488-AcLDL) 
Early passage (2-4) bovine vessel wall derived ECs and corneal ECs were 
incubated with 10 µg/mL of 488-AcLDL (Invitrogen) in the media for 8 hours at 
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37°C. Cells were washed three times, co-stained with 1.5µg/mL of the nuclear 
stain, 4’, 6-diamidino-2-phenylindole dihydrochloride (DAPI) (Sigma), and 
examined by inspection through an inverted fluorescence microscope (Zeiss, 
Thornwood, NY) at 40 x magnification. 
 
Tube formation assay 
Capillary tube formation by the various ECs was performed as previously 
described using Matrigel coated dishes (Ingram et al 2004). Early passage (2-4) 
bovine vascular ECs and corneal ECs were seeded onto 96-well tissue culture 
plates coated with 30µl Matrigel (BD Biosciences) at a cell density of 10,000-
30,000 cells per well. Cells were observed every two hours by an inverted 
microscope for the formation of capillary-like structure. 
 
RT-PCR  
Total cellular RNA was extracted with TRIzol (Invitrogen) in a single-step method 
as described by the manufacturer. RT reactions were performed using a 
SuperScript First-Strand Synthesis system (Invitrogen). PCR was conducted 
using Go Tap Flexi DNA Polymerase (Promega, Madison, WI) according to the 
manufacturer’s instructions. The primer sequences were shown in Table II.1. The 
PCR cycle was 94°C, 5 min; 94°C 30s, 53 or 57 or 59°C (depending on the 
different primers) 30s, 72°C 45s, and 32 cycles with a final 72°C 7 min cycle.  
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PCR products were added to wells in a 2% agarose/ethidium bromide gel, 
exposed to electophoresis current, and migrating bands were photographed 
under UV light. 
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Gene Forward Reverse Tm Product size 
S100B GGTGACAAGCACAAGCTGAA CAGTGGTAATCATGGCAACG 55 184 
Enolase 2 GGACTTGGATGGGACTGAGA GCGTCCTTGCCATACTTGTC 57 327 
N-Cadherin AGCAACTGCAATGGGAAAAG GATGGGAGGGATAACCCAGT 55 461 
VE-Cadherin GAGTGTGGACCCCAAGAAGA GCTGGTACACGACAGAAGCA 57 359 
eNOS TGAGCAGCTGCTGAGCCAGG CAGCTCGCTCTCTCGGAGGT 57 209 
PECAM I ATGTGCTGCTTCACAACGTC TGAATTCCAGCGTCACAAAA 53 345 
Vimentin CTTCGCCAACTACATCGACA GGATTCCACTTTACGCTCCA 55 340 
Enolase 1 GCAGGAGAAGATCGACAAGC GTAAACCTCTGCTCCGATGC 57 310 
ZO 1 GAATCCGATGTGGGTGATTC GCAGGTTTCTCTTGGAGCTG 57 310 
Factor Viii ACTGCCTCATCCCACTTACG GGGGTCTAGAGCATTCACCA 57 327 
GAPDH GGTGAAGGTCGGAGTGAACG GGGTCATTGATGGCGACGA 59 117 
LDLR ACAACCCCGTGTACCAGAAG AGGGTCAGGGGAGAAAGTGT 57 195 
CD36 AACCACTTTCATCAGACCCG ACGTGTCATCCTCAGTTCCA 57 475 
Table II.1: Primers used for conventional RT-PCR 
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Single cell clonogenic assay 
Early passage (2-4) bovine vascular ECs and corneal ECs, were selected by size 
and cell complexity using a FacsVantage Sorter (Becton Dickinson) and 
deposited as one cell per well into 96 well plates pre-coated with type I rat tail 
collagen in 200µl of media as previously described (Huang et al 2007). Cells 
were cultured at 37°C, 5% CO2 in a humidified incubator. Media was changed 
every five days. After 14 days of culture, the cells were fixed with 4% 
paraformaldehyde (Sigma, St. Louis, MO) in DPBS for 30 minutes at room 
temperature, then washed twice and stained with 1.5 µg/ml DAPI, and examined 
for determination of EC number. Those wells containing two or more cells were 
identified as positive for proliferation under a fluorescent microscope at 10x 
magnification. Culture wells containing fewer than 50 cells were counted by direct 
visual inspection with a fluorescent microscope at 10x magnification. For those 
wells with more than 50 cells, colonies were imaged and cell number quantified 
using an Image J 1.36v program (Wayne Rasband, NIH). 
 
Sphere forming assay 
Early passage (1-2) bovine corneal ECs were released from adhering to the 
culture dish using TryPLE and then suspended into single cells in the culture 
medium. Cells were seeded at a density of 50cells/µl on plastic dishes as 
hanging drops (10 µl each) to allow spheroid formation by cell aggregation. Cells 
then were cultured at 37°C, 5% CO2 in a humidified incubator 3 days. Under this 
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condition, the suspended cells contributed to formation of a single spheroid per 
drop of defined size (diameter > 100µm).  
 
Telomerase assay 
Telomerase activity was measured by the telomeric amplification protocol 
(TRAP) as previously described (Kim et al 1994) using the TRAPeze telomerase 
detection kit (Chemicon, Temecula, CA). Cells lysate from 1000 cells were used 
in each assay. Hela cell extract served as a positive control and lysis buffer only 
as negative control. The PCR products were exposed to an electrophoretic 
current on a 12.5% non-denaturing polyacrylamide gel and visualized by SYBR 
gold staining (Molecular Probe, Eugene, OR). 
 
Statistical Analysis 
Results are expressed as mean±SEM for the study variables. Data were 
compared with ANOVA test and significant differences were set at the P < 0.05 
level. All analyses were performed using GraphPad InStat software (GraphPad 
Software Inc, La Jolla, CA)
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Results 
Characterization of BCECs compared to bovine vascular endothelial cells 
BCECs have been successively isolated and expanded in vitro. We isolated and 
cultured BCECs from 18 and 24 month old mixed breed steers and identified the 
samples as BCEC 18 and BCEC 24, respectively. These primary cultured 
BCECs displayed a typical hexagonal morphology (similar to the endothelial 
morphology in the intact cornea by direct visualization) at confluence. In 
comparison, bovine ECs from aorta, coronary artery, and pulmonary artery 
exhibited more morphological heterogeneity with more spindle-shaped and large 
oval cells (Figure II.1). 
 
To determine whether ECs displayed any common hematopoietic antigens, we 
examined BCECs as well as bovine vascular ECs for expression of the leukocyte 
common antigen CD45 (known to be expressed on all nucleated blood cells). 
None of the endothelial cells expressed CD45 while the peripheral blood low 
density MNC (comprised of leukocytes) highly expressed CD45 (Figure II.2A). 
BCECs and bovine vessel wall derived ECs were able to bind LEL while 
peripheral blood MNCs did not display this activity (Figure II.2A). Additionally, 
BCECs, vascular ECs, and MNCs were all able to bind GSL I (Figure II.2A). 
Actually, BCECs and bovine vascular ECs had the same lectin binding pattern for 
all 30 lectins tested (data not shown). Thus BCECs share some cell surface 
molecule expression with bovine vessel wall derived ECs but there is no 
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evidence that any of the ECs express the most common hematopoietic antigen 
CD45. 
 
Ingestion of AcLDL is a feature displayed by many ECs and not surprisingly, all 
bovine vessel wall derived ECs readily ingested the lipoprotein complex (Figure 
II.2B). In contrast, BCECs were unable to ingest AcLDL (Figure II.2B). The LDL 
receptor (LDLR) and scavenger receptors, such as CD36, mediate native and 
modified LDL-ingestion. We further examined LDLR and CD36 expression in 
bovine vascular and corneal endothelial cells after exposing the endothelial cells 
to AcLDL. LDLR transcripts were detectable in both types of ECs while CD36 
transcripts were only present in vascular ECs after 8h of exposure to AcLDL 
(Figure II.2C). Capillary-like tube formation is another feature displayed 
essentially by all vascular ECs when examined in vitro. Surprisingly, BCECs, 
similar to all of the bovine vascular ECs, readily formed capillary-like structures 
when plated on Matrigel-coated dishes (Figure II.2D). Therefore, while BCECs 
always exist as a flattened monolayer lining the most posterior aspect of the 
cornea in vivo, removal of the cells and replating in vitro permits some functional 
properties of vascular ECs to emerge from the corneal ECs. 
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Figure II.1 The morphology of cultured bovine vessel wall derived ECs 
and bovine corneal ECs. Bovine vascular ECs derived from aorta (BAECs), 
coronary artery (BCAECs) and pulmonary artery (BPAECs) display spindle 
shape morphology and BCECs present a hexagonal monolayer. (10x 
magnification, scale bar represents 100µm) 
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Figure II.2 Phenotypic and functional characterization of bovine vessel 
wall derived ECs and bovine corneal ECs. (A) Immunophenotyping of bovine 
peripheral blood MNCs and the monolayers derived from BAECs, BCAECs, 
BPAECs and BCECs by fluorescence cytometry. BAECs, BCAECs, BPAECs 
and BCECs can bind to the lectins GSL I and LEL but do not express common 
leukocyte antigen CD45. Negative controls are overlayed in green on each 
histogram. (B) Incorporation of 488-AcLDL in bovine vessel wall derived ECs 
and corneal ECs. BAECs, BCAECs and BPAECs are able to ingest 488-AcLDL 
(green) but not BCECs. The cell nuclei are stained with DAPI (blue). (40x 
magnification, scale bar represents 100µm) (C) LDLR and CD36 expression in 
bovine vascular and corneal ECs after exposed to AcLDL using RT-PCR. LDLR 
is expressed in all types of ECs while CD36 is only detectable in bovine 
vascular ECs after ingesting AcLDL. (D) Formation of capillary-like structures 
when bovine vascular ECs and BCECs are plated in Matrigel. (40x 
magnification, scale bar represents 100µm) Three independent experiments 
show similar results. 
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Gene expression of BCECs compared to bovine vascular endothelial cells 
Although corneal ECs and vascular ECs possess differences in developmental 
origin, anatomic location, and physiological function, they have showed some 
similarities in phenotype and function in the above studies. To further compare 
and contrast these sources of ECs, we interrogated all of the EC lines for the 
expression of certain mRNA transcripts that are published as commonly 
expressed in all vascular endothelial cells (Figure II.3) (Albelda et al 1991, Huang 
et al 2007, Ohashi et al 2007). Remarkably, BCECs did not express vascular 
endothelial-cadherin (VE-Cadherin), nitric oxide synthase 3 (endothelial nitric 
oxide synthase; eNOS) or platelet/endothelial cell adhesion molecule 1 
(PECAM1) which are expressed in bovine vascular ECs derived from aorta, 
coronary artery, and pulmonary artery. While there has been no single specific 
genetic marker for corneal ECs yet identified, we have scanned the published 
literature and identified numerous genes, including S100B, enolase2, N-cadherin, 
vimentin, ZO-1 and factor VIII, which are reportedly expressed preferentially in 
corneal ECs. S100B mRNA was present in BCECs and BPAECs, but absent in 
BAECs and BCAECs. Neuron specific enolase 2 mRNA was present in BCEC 18 
and BCAECs and in three experiments, detectable in BCEC 24 but at the low 
level of detection. N-Cadherin mRNA was present in all ECs except BAECs. 
Furthermore, vimentin, enolase1, ZO1 and factor VIII mRNA were detectable in 
all ECs. Thus, BCECs displayed a gene expression profile that differed 
somewhat from bovine aortic, coronary artery, and pulmonary artery ECs, 
however, no one single gene product was BCEC specific. Whether these 
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differences are related to the known influence of in vitro culture on modulating 
gene expression and cell function in all the endothelial cells tested or truly 
represent tissue specific differences in gene expression will require further 
search for specific markers for these different endothelial populations that 
permits prospective isolation from each tissue and gene expression interrogation. 
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Figure II.3 RT-PCR analysis of gene expression in bovine vessel wall 
derived ECs and bovine corneal ECs. PECAM1, VE-Cadherin and eNOS are 
specifically expressed in bovine vascular ECs but not in corneal ECs. S100B 
transcripts are detectable in BCECs but not in vessel wall derived ECs. 
Enolase2 are also can be detected in BCECs with variable expression level. 
The other genes related to corneal ECs can also be detected in vascular ECs. 
Three independent experiments show similar results. 
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Hierarchical organization of the proliferative potential in BCECs and bovine 
vascular endothelial cells 
We have recently developed a single cell clonogenic assay to quantitate the 
proliferative capacity of individual ECs. Using this method, we have defined a 
hierarchy of ECFCs present in both circulating and vessel wall derived ECs in 
human subjects and other vertebrates. Here we tested whether bovine vessel-
derived ECs and corneal ECs possessed a similar hierarchy of cells with varying 
levels of proliferative potential. It was apparent that vascular ECs and corneal 
ECs displayed diverse proliferative ability at a clonal level. Some ECs did not 
divide and some divided and gave rise to various sized colonies of endothelium 
(Figure II.4). Significantly more single BAECs executed at least one cell division 
during 14 days of culture compared to BCECs (BAECs vs. BCEC 18 vs. BCEC 
24 was 65.67 ± 2.52% vs. 32.63 ± 1.22% vs. 41.40 ± 5.24%). However, there 
was no significant difference in the frequency of dividing cells among BAECs, 
BCAECs (48.00 ± 4.67%) and BPAECs (46.93 ± 7.46%) or among BCAECs, 
BPAECs and BCECs (Figure II.4A). Surprisingly, 39.82 ± 2.71% of the individual 
BCEC 18 and 43.25 ± 3.49% of the individual BCEC 24 cells that divided gave 
rise to well circumscribed colonies containing more than 10,000 progeny in the 2 
weeks’ assay. This frequency was significantly higher than that measured for 
individually plated BAECs (33.67 ± 4.22%). Differences in the ECFC distribution 
were observed in BCEC 18 cells versus BCEC 24 cells (at the same passage 
number), suggesting that some variability may be observed between donors with 
respect to this kind of distribution analysis.  
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We recently defined HPP-ECFCs as cells that can yield macroscopic colonies (at 
least more than 2000 cells) and can also form secondary HPP-ECFC colonies 
upon replating. To examine whether any BCECs or bovine vascular ECs possess 
HPP-ECFC activity, the progeny of primary ECFC colonies containing more than 
10,000 cells were trypsinized and replated into 96-well tissue culture plates at 
one cell per well. After another 14 days of culture, the individually replated cells 
generated all sizes of colonies including some colonies containing more than 
10,000 cells (data not shown). Thus a complete hierarchy of ECFCs was 
identified in BCECs and bovine vascular ECs, and these ECFC-derived progeny 
were comprised of non-dividing mature ECs, endothelial clusters (2-50 
cells/colony), low proliferative potential-ECFCs (LPP-ECFCs, 51-2000 
cells/colony) and HPP-ECFCs (2001 or greater cells/colony). 
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Figure II.4 Quantitation of the clonogenic and proliferative potential of 
single endothelial cells derived from bovine vascular endothelium and 
bovine corneal endothelium. (A) The percentage of single BAECs, BCAECs, 
BPAECs and BCECs dividing at least once after 14 days culture. There are 
significantly fewer BCECs undergoing division comparing to bovine vessel wall 
derived ECs. (B) The distribution of different size of colonies derived from 
single ECs in an individual well after 14 days of culture. There is dramatically 
higher percent of HPP-ECFCs than LPP-ECFCs and endothelial clusters in 
BAECs and BCECs. *P < 0.05, **P < 0.01, ***P < 0.001 by parametric ANOVA. 
(n=3) 
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High levels of telomerase activity in BCECs and bovine vascular 
endothelial cells 
We have previously reported that human cord blood HPP-ECFC possesses high 
levels of telomerase activity. Remarkably, the progeny of HPP-ECFC isolated 
from BCECs displayed telomerase activity similar to that of the progeny of HPP-
ECFC derived from BAECs, BCAECs and BPAECs (Figure II.5). Thus, HPP-
ECFCs in both BCECs and bovine vascular ECs express quantifiable levels of 
telomerase activity suggesting a potential mechanism through which proliferative 
potential is retained within the subset of endothelial cells that possess 
proliferative potential. 
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Figure II.5 Telomerase activity of HPP-ECFCs derived from bovine vessel 
wall derived ECs and BCECs. P indicates telomerase activity in Hela cells, 
which acts as a positive control, N indicates a negative control and IC indicates 
internal control. Three independent experiments show similar results. 
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Sphere forming ability displayed by BCECs 
Human and rabbit corneal ECs have been reported to form sphere colonies in 
vitro (Mimura et al 2005, Yokoo et al 2005). Sphere formation has often been 
used as a surrogate assay to reflect the presence and frequency of stem and/or 
progenitor cells for the lineage under investigation (Ramirez-Castillejo et al 2006, 
Reynolds & Weiss 1992, Tropepe et al 2000, Xu et al 2009). Herein, we 
described that low passage cultured BCECs were able to form in vitro spheres 
(Figure II.6A) with an excellent efficiency of 53 ± 10 spheres per 100,000 cells 
after 3 days of culture. To interrogate the spheres for evidence of the clonal 
proliferative potential of the endothelial cells, 3 day old primary spheres were 
dissociated and cells were plated into a single cell clonogenic assay. Among 
3000 sphere-derived single BCECs plated, only 9.58 ± 6.09% survived at the 
single cell level. However, 90.43 ± 6.56% of the surviving cells demonstrated the 
ability to divide at least once and form ECFC-derived colonies of varying sizes. 
We noted that the complete hierarchy of ECFCs was identified in sphere-derived 
BCECs and the distribution of proliferative potential was similar to that in primary 
cultured BCECs (Figure II.4B). Thus, these corneal endothelial spheroids are 
comprised of non-dividing mature ECs, endothelial clusters, LPP-ECFCs, and 
HPP-ECFCs (Figure II.6B). Therefore, while the majority BCECs that formed 
spheres in vitro failed to survive at a single cell level, those surviving cells 
retained a similar distribution of proliferative potential as the BCECs used to 
establish the in vitro sphere. 
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Figure II.6 The formation of sphere colony by bovine corneal endothelial 
cells. (A) Representative photograph of sphere derived from plated BCECs. 
(Scale bar represents 100µm) (B) The distribution of different size of colonies 
derived from single BCECs dissociated from corneal endothelial sphere colonies 
in an individual well after 14 days of culture. The complete hierarchy of ECFC is 
present in BCECs residing in the spheres. 
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Discussion 
It is well known that corneal ECs are apparently restrained from proliferating in 
vivo, but they retain proliferative potential and can be expanded in vitro. The 
present study is the first to demonstrate that not all corneal ECs display the same 
ability to proliferate at a clonal level. In fact, we define a hierarchy of ECFCs in 
bovine corneal ECs based on their proliferative potential using a single-cell 
clonogenic assay. We report that the distribution of ECFCs derived from single 
BCECs is quite similar to bovine vascular endothelium from aorta, coronary 
artery, and pulmonary artery and is consistent with circulating and resident 
vascular endothelial cells in adult human subjects.  
 
The proliferative activity of corneal endothelium in vitro has been observed under 
a variety of in vitro conditions. EDTA can release endothelial cells from contact 
inhibition and promote proliferation within the endothelial monolayer (Joyce & 
Zhu 2004, Senoo et al 2000). Cytokines such as epidermal growth factor (EGF) 
and nerve growth factor (NGF) can also induce corneal ECs proliferation in vitro 
(Joyce & Zhu 2004). Furthermore, the overexpression of oncogene proteins 
(SV40 large T antigen or E6/E7) or the transcription factor E2F2 in corneal ECs 
can induce proliferation (Joyce 2003, McAlister et al 2005). These observations 
indicate that at least some corneal ECs inherently possess high proliferative 
capacity. Most recently, Mimura and colleagues (Mimura & Joyce 2006) have 
reported that peripheral corneal ECs display more proliferative capacity than 
those more centrally located. Moreover, Mimura and Yamagami (Mimura et al 
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2005, Yamagami et al 2007) demonstrated that there are a greater number of 
corneal EC precursor cells in the periphery than in the center by performing a 
sphere-forming assay, and concluding that the higher frequency of sphere-
forming ability in the periphery must be related to the retention of precursor cells. 
However, these important studies did not use a single cell clonogenic assay, 
which can quantitatively and stringently interrogate the proliferative potential of 
individual ECs, to test whether corneal ECs harbored different populations that 
could be distinguished by their clonogenic potential. 
 
Since we previously identified the entire hierarchy of ECFCs in circulating and 
vessel-derived ECs in human, pig and rat, it’s not surprising that this hierarchy of 
proliferation is also present in bovine vascular ECs. However, it is of interest that 
corneal ECs can also be discriminated by similar proliferative and clonogenic 
properties. In the present study, we have provided evidence that corneal 
endothelial HPP-ECFC give rise to all subsequent stages of ECFC development.  
Thus, corneal endothelium possesses the complete hierarchy of ECFCs, and 
HPP-ECFCs display properties of a corneal endothelial progenitor cell as they 
have the most proliferative capacity and can be cultured in vitro in the absence of 
stroma cells. 
 
The existence of stem cells for the corneal endothelium has been reported 
recently. By using telomerase activity assay and BrdU (bromodeoxyridine) 
incorporation assay, Whikehart et al (Whikehart et al 2005) argued that the 
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putative stem cells for corneal endothelium are located in a niche at the posterior 
limbus between the peripheral endothelium and the trabecular meshwork (TM). 
More recently, McGowan et al (McGowan et al 2007) provided further evidence 
for the presence of such a population in this area by demonstrating the 
expression of stem cell markers (nestin, Oct-3/4 and Wnt-1) in the unwounded 
cornea. They observed that the differentiation markers (Pax-6, Sox-2) were 
induced in this area and extended to peripheral corneal endothelium after 
wounding, which suggested that these putative stem cells respond to corneal 
damage and initiate endothelial repair. However, Mimura and Yokoo recently 
demonstrated that they were able to isolate corneal endothelial precursor cells 
from corneal endothelium with a sphere-forming assay and that the corneal 
endothelium harbors precursor cells which exhibit high proliferative capacity, 
form colonies in a sphere-forming assay, and have self-renewal ability to give 
rise to the secondary colonies (Mimura et al 2005, Yokoo et al 2005). Additionally, 
the sphere-forming ability of the peripheral corneal ECs was reported to be 
greater than centrally located ECs (Mimura et al 2005, Yamagami et al 2007). 
Moreover, the progeny of isolated spheres display hexagonal morphology and 
transport activity.  
 
Although a sphere-forming assay has been extensively utilized to quantitatively 
measure stem cell frequency in many fields including neural stem cells and 
cancer stem cell (Ramirez-Castillejo et al 2006, Reynolds & Weiss 1992, 
Tropepe et al 2000, Xu et al 2009), recent studies have indicated that not all cells 
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capable of forming a sphere meet the criteria for a stem cell (Singec et al 2006). 
Moreover, the in vitro conditions to form spheres often permits the highly motile 
spheres to merged together, which argues against these spheroid structures 
arising from a single stem cell (Singec et al 2006). Therefore, use of a sphere-
forming assay may not permit accurate determination of which individual cells 
display proliferative potential. In our current study, we utilized a single cell 
clonogenic assay to provide direct evidence that corneal EC precursors exist in 
corneal endothelium. HPP-ECFCs display the property of corneal endothelial 
progenitor cells as they have the most clonal proliferative capacity, can be 
replated to form secondary HPP-ECFC, and give rise to all other ECFC colonies 
and/or mature non-dividing endothelium. Whether the peripheral corneal 
endothelium harbors more HPP-ECFCs than the central endothelium needs to be 
further examined and is currently being investigated in our lab.  
 
In this study, we did not directly isolate sphere colonies from bovine corneal 
endothelium. Instead, we tried to generate corneal endothelial spheroids from 
plated BCECs from low passage cultures (passage 1 or 2). We noticed that 
without addition of fetal calf serum to the culture medium, isolated cells only 
aggregated but did not form spheres. Furthermore, when plated in the floating 
culture method as previously described (Mimura et al 2005, Yamagami et al 2007, 
Yokoo et al 2005), BCEC frequently became free of the sphere and reattached to 
the culture substrate. Thus, we had to use a hanging drop method of sphere 
formation that was modified from previous publications (Del Duca et al 2004, 
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Timmins & Nielsen 2007). Under these culture conditions, BCECs were able to 
form numerous spheres when 500 cells were deposited per drop of medium. This 
number is much lower than reported for a human corneal endothelial cell sphere-
forming assay, where 257 ± 83 spheres were generated from 50,000 cells after 
10 days of culture (Yokoo et al 2005). This might be due to obvious differences in: 
1) culture conditions, 2) species, 3) use of freshly isolated corneal ECs versus 
plated corneal ECs. It is of interest that BCECs residing in the spheres displayed 
the complete hierarchy of ECFC (Figure II.6B) when examined clonally, and the 
distribution of proliferative potential was similar to BCECs that were resident in 
corneal endothelium prior to plating (Figure II.4B). Taken together, we propose 
that a single cell clonogenic assay is an alternative method to stringently and 
directly quantitate corneal endothelial progenitor cell residence. 
 
Consistent with their great proliferative ability, HPP-ECFCs in corneal 
endothelium display high levels of telomerase activity (Figure II.5). The telomere 
length in corneal endothelium has been measured in vivo and in vitro. In human 
subjects, the average telomere length has been reported as 11-14kb (Amano 
2003, Egan et al 1998). It should be realized that there was no statistically 
significant difference in the telomere length of the corneal ECs residing in the 
central and peripheral areas of freshly examined corneal endothelium or when 
corneal EC from younger and older age groups were compared (Amano 2003, 
Egan et al 1998, Konomi & Joyce 2007). These observations have been 
interpreted as evidence that the limited replicative ability of corneal ECs 
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displayed in vivo is not due to senescence caused by successive shortening of 
telomeres. In contrast, it has been reported that in vitro passaging does shorten 
the telomere length in cultured corneal ECs (Amano 2003, Whikehart et al 2005), 
which leads to replicative senescence. 
 
Corneal endothelium is formed by migration and proliferation of neural crest-
derived mesenchymal cells and plays a barrier-bump function to maintain corneal 
clarity. Their developmental origin, anatomical localization and physical function 
are completely different from vascular ECs. Thus these two types of endothelial 
cells would be expected to exhibit different gene expression and functional 
properties. We report that VE-Cadherin, PECAM1 and eNOS which are specific 
markers associated with human vascular ECs are not expressed in human 
corneal ECs at the transcriptional level (Figure II.3), although Scheef et al. 
(Scheef et al 2007) reported that VE-Cadherin can be expressed in murine 
corneal ECs. The disparity of VE-Cadherin expression might be due to the 
difference between these two species. While incorporation of AcLDL is an 
important property of vascular ECs, Elner and Chang reported that corneal EC 
ingest native circulating LDL (Chang et al 1991, Elner et al 1991) but not 
chemically modified lipoproteins such as AcLDL. Our data, consistent with these 
previous studies, demonstrated that corneal ECs cannot incorporate AcLDL, 
which might be result from the absence of expression of the scavenger receptors 
CD36. Perhaps most surprising, bovine corneal ECs formed capillary-like 
structures when plated in Matrigel which is a characteristic of vascular ECs. All 
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these observations indicate that although corneal ECs are not exposed to the 
same environment as vascular ECs in vivo, they are flexible and are able to 
acquire some vascular ECs properties if given appropriate stimuli in vitro. This 
poses an intriguing possibility that, if vascular ECs can be manipulated to display 
corneal ECs characteristics, they may serve as an alternative autologous cell 
source for repair of damaged or senescent corneal endothelium.  
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CHAPTER III 
Human Cord Blood Plasma Can Replace Fetal Bovine Serum (FBS) for in 
vitro Expansion of Functional Human Endothelial Colony Forming Cells 
(ECFCs) 
Introduction 
The progenitor cells for the endothelial lineage play critical roles in vascular 
homeostasis and regeneration in adult subjects (Asahara et al 1997, Hirschi et al 
2008, Khakoo & Finkel 2005, Kovacic et al 2008, Rafii & Lyden 2003). High 
proliferative potential endothelial colony forming cells (HPP-ECFCs) have been 
identified as endothelial progenitor cells (EPCs) with robust proliferative potential 
in vitro and vessel-forming ability in vivo (Ingram et al 2004, Yoder et al 2007). 
Additionally, recent studies reveal that the concentration of ECFCs in circulation 
increases after vascular ischemia, which implies a possible contribution to 
vascular repair (Guven et al 2006, Huang et al 2007). Thus, ECFCs become an 
attractive target for new vascular regenerative therapies. However, the study of 
ECFCs is hampered by multiple challenges in culturing the cells. 
 
Current protocols for in vitro expansion of ECFCs mostly depend on the 
presence of fetal bovine serum or fetal calf serum (FBS or FCS) in the culture 
medium. Our preliminary data (Grimes BR, manuscript in preparation) has 
indicated that a high concentration of FBS destabilizes chromosomes in ECFCs 
and the frequency of the diploid karyotype decreases, while tetraploid or 
aneuploid karyotypes increase in ECFCs cultured in increasing concentrations of 
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FBS (Corselli et al 2008). Moreover, we found that differential expression of 
some arterial and venous endothelial cell (EC) gene markers in freshly isolated 
arterial and venous EC becomes indistinct when these cells are plated in a 
culture containing a high concentration of FBS (Figure III.1). This observation 
suggests that FBS might modify gene expression in ECFCs, and thus may affect 
cell properties and functions. In addition, FBS/FCS may contain potentially 
harmful xenogenic compounds associated with risks of transmitting infectious 
agents and inducing immune reactions when used in a transplantation setting 
(Halme & Kessler 2006, Mannello & Tonti 2007). Based on research and clinical 
considerations, a well-defined, serum-reduced or serum-depleted culture medium 
for in vitro isolation and expansion of ECFCs is greatly needed. 
 
Human blood derivatives have been considered as alternatives to FBS. Human 
autologous or allogeneic serum/plasma, human umbilical cord serum, platelet 
enriched plasma, platelet lysate and platelet-released growth factors have been 
used as supplements in culture media to promote proliferation, migration and 
differentiation of mesenchymal stromal stem cells (MSCs) (Bieback et al 2009, 
Doucet et al 2005, Kilian et al 2004, Muller et al 2006, Vogel et al 2006). 
Similarly, human platelet lysate (Reinisch et al 2009, Reinisch & Strunk 2009) or 
platelet-derived growth factors (Kilian et al 2004) are able to enhance 
proliferation and migration of ECs and retain their vessel-forming ability. 
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In this study, we describe a novel culture medium supplemented with six growth 
factors and 1.5% human cord plasma, to efficiently recover ECFCs from human 
cord blood mononuclear cells (MNCs). We call this medium serum reduced 
medium (SRM). We demonstrate that ECFCs can be propagated in SRM, 
retaining their endothelial phenotype and function. When cultured in SRM, 
ECFCs exhibit the complete hierarchy of proliferative potential distribution and 
maintain genomic stability.  
79 
 
 
 
Figure III.1 The expression of arterial and venous specific genes in human 
umbilical artery and vein endothelial cells (HUAEC and HUVEC). The distinct 
arterial and venous gene expression patterns are exhibited in freshly isolated 
HUAECs and HUVECs, but these patterns become indistinct when cells are 
cultured in complete endothelial growth medium-2 (cEGM-2) containing 10% 
defined FBS.  
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Materials and Methods 
Media and supplements 
Human Endothelial Serum Free Medium (SFM; Invitrogen, Grand Island, NY) 
was supplemented with 20 ng/ml human recombinant basic fibroblast growth 
factor (hrbFGF) (Invitrogen), 10 ng/ml human recombinant epidermal growth 
factor (hrEGF) (R&D, Minneapolis, MN), 10 ng/ml vascular endothelial growth 
factor 165 (VEGF165) (R&D), 10 ng/ml VEGF121 (R&D), 10 ng/ml stem cell factor 
(SCF) (R&D), 5 ng/ml stromal cell derived 1 alpha (SDF1 α) (R&D), 10 ng/ml 
interleukin 6 (IL6) (R&D) and 1.5% human umbilical cord plasma (HCP), to 
create our serum-reduced medium (SRM). As a control, human EGM-2 medium 
(Lonza, Walkersville, MD) was supplemented with 10% FBS (Hyclone, Logan, 
UT) and 1.5% penicillin/streptomyocin (Invitrogen), and called complete EGM-2 
medium, or cEGM-2. 
 
Preparation of pooled HCP 
Human umbilical cord blood (UCB) samples (50-100 mL) were collected in 
heparin-coated syringes (20 to 30 USP units of heparin/mL of blood) from healthy 
newborns (38- 40 weeks gestation). The Institutional Review Board at Indiana 
University School of Medicine reviewed and approved this study with exempt IRB 
status. UCB was diluted 1:1 with Dulbecco’s Phosphate Buffered Saline (DPBS) 
(Invitrogen) and overlaid onto Ficoll-Paque PLUS (GE Healthcare, Piscataway, 
NJ) according to the manufacturer’s instructions. Cells were centrifuged for 30 
minutes at room temperature at 1500 rpm. After centrifugation, the mononuclear 
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cells (MNCs) were collected for culturing endothelial cell colonies, and the 
supernatant was collected for preparing human cord plasma (HCP). 
Subsequently, the supernatant was aliquoted and frozen at -80°C. After thawing, 
aliquots with the same volume from at least 20 samples were pooled and sterilely 
filtered through a 0.2 µm filter. The pooled HCP was then added to SRM.  
 
Isolation and culture of UCB-derived ECFCs 
MNCs were isolated and washed with DPBS. For outgrowth of ECFC colonies, 
MNCs either were resuspended in SRM or cEGM-2 medium. MNCs (3 x 107 
/well) were seeded onto 6-well tissue culture plates precoated with Type I rat-tail 
collagen (BD Biosciences; Bedford, MA) and cultured as previously described 
(Ingram et al 2004). Spindle-shaped ECFC colonies emerged sequentially from 
the MNCs and the first day of ECFC colony emergence was recorded. The 
frequency of ECFC colonies was determined by measuring the total number of 
colonies in the primary culture on day 10 (as no ECFC ever emerged at a later 
timepoint). Subsequently, the ECFC-derived ECs were released from the primary 
culture dish by TrypLE™ Express (Gibco, Grand Island, NY) and replated onto 
25 cm2 tissue culture flasks pre-coated with Type I rat-tail collagen for 
subsequent passage. 
 
Immunophenotyping of ECFC derived ECs 
Early passaged (1-2) ECFC-derived ECs (5 x 104) were incubated at 4°C for 30 
minutes in 100 µl of medium with varying concentrations of the primary or isotype 
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control antibody as outlined below, washed three times, and analyzed by 
fluorescence-activated cell sorting (FACS) (Becton Dickinson, San Diego, CA). 
The primary antibodies we used included anti-human CD31 conjugated to 
phycoerythrin (PE) (BD Biosciences Pharmingen; Bedford, MA), anti-human 
CD34 conjugated to allophycocyanin (APC) (BD Biosciences Pharmigen), anti-
human CD144 conjugated to PE (BD Biosciences Pharmingen), anti-human 
CD146 conjugated to PE (BD Biosciences Pharmingen), anti-human cKIT 
conjugated to APC (eBioscience; San Diego, CA), anti-human VEGFR1 
conjugated to PE (BD Biosciences Pharmingen), anti-human VEGFR2 
conjugated to fluorescein isothiocyanate (FITC) (BD Biosciences Pharmingen), 
anti-human VEGFR3 conjugated to APC (R&D), anti-human Nrp1 conjugated to 
PE (Miltenyi Biotec; Auburn, CA), anti-human Nrp2 (R&D) conjugated to Alexa 
Fluor 647 (Molecular Probes, Eugene, OR), anti-human CD14 conjugated to PE 
(BD Biosciences Pharmingen), anti-human CD45 conjugated to FITC (BD 
Biosciences Pharmingen), anti-human AC133 conjugated to APC (Miltenyi 
Biotec) and anti-human CXCR4 conjugated to FITC (BD Biosciences 
Pharmingen). For negative controls, we used directly conjugated mouse IgG 
isotypes (BD Biosciences Pharmingen).  
 
FISH analysis of interphase cells 
ECFC derived ECs after 30 days of culture from initiation (representing 
approximately 15 population doubling) were collected and resuspended in 
hypotonic solution, followed by fixation in 3:1 w/v methanol acetic acid and 
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dropped onto microscope slides, as previously described (Grimes et al 2009). 
Probes specific to the centromeres of chromosome 17 (CEP 17, Spectrum 
Green) and chromosome X (CEP X, Spectrum Orange) were purchased from 
Abbott Molecular Inc. (Des Plaines, IL). Following probe hybridization and 
washes, cells were counterstained with 4’,6-diamidino-2-phenylindole (DAPI; 
Vector Labs, Burlingame, CA). The signals obtained with the 17 and X probes 
indicating at least 200 interphase nuclei per experiment were counted using a 
Leica DM5000B fluorescent microscope (Leica Microsystems; Bannockburn, IL). 
Images were captured with a Spot RTKE camera (Diagnostic Instruments; 
Sterling Heights, MI) at 100x magnification. 
 
Single cell clonogenic assays 
Early-passage (1-2) ECFC-derived ECs were plated at one cell per well into 96 
well plates pre-coated with Type I rat-tail collagen in 200 µl of cEGM-2 medium. 
Cells were cultured at 37°C in a humidified incubator with 5% CO2. Media were 
changed every five days. After 14 days of culturing, cells were fixed with 4% 
paraformaldehyde (Sigma; St. Louis, MO) in phosphate-buffered saline for 30 
minutes at room temperature, then washed twice, stained with 1.5 µg/ml DAPI, 
and examined for the growth of ECs. Those wells containing two or more cells 
were identified as positive for proliferation under a fluorescent microscope at 10x 
magnification. Wells containing fewer than 50 cells were counted by visual 
inspection with a fluorescent microscope at 40x magnification. For those wells 
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with more than 50 cells, colonies were imaged and cell number quantified using 
an Image J1.36v program (Wayne Rasband, NIH). 
 
In vivo matrix implantation assays  
Early-passaged (3-5) ECFC-derived ECs (2 x 106 cells/mL) were suspended in a 
1.5 mg/mL collagen-fibronectin matrix as previously described (Yoder et al 2007). 
Aliquotes (250µl) were pipetted into wells of 48 well plates, allowed to polymerize 
at 37°C for 30 minutes, and covered with 500µl of culture medium for overnight 
incubation at 37°C, in 5% CO2. After 18 hours of ex vivo culture, cellularized 
matrices were implanted into the flanks of 6- to 8-week-old NOD/SCID mice as 
previously described (Yoder et al 2007). After 14 days, mice were euthanized 
and the grafts were harvested, fixed in formalin-free zinc fixative (BD 
Biosciences), paraffin embedded, bisected, and sectioned (6 µm) for analysis by 
histology and immunohistochemistry (n=6).   
 
Histology and Immunohistochemistry 
Sections were stained as previously described (Yoder et al 2007). Paraffin-
embedded tissue sections were deparaffinized and then either directly stained 
with hematoxylin and eosin (H&E) or immersed in retrieval solution (Dako, 
Carpenteria, CA) for 20 minutes at 90-99°C. Slides were incubated at room 
temperature for 30 minutes with anti-human CD31 (clone JC70/A, Abcam), 
followed by a 10-minute incubation with LASB2 link-biotin and streptavidin-HRP 
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(Dako), then developed with DAB (Vector, Burlingame, CA) solution for 5 
minutes.  
 
Statistical Analysis 
Results are shown as the mean ± the standard error of the mean (SEM). Data 
were analyzed with ANOVA; parametric test and significant differences were set 
at P < 0.05. All analyses were performed using GraphPad InStat software 
(GraphPad Software Inc. La Jolla, CA).
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Results 
Isolation and expansion of human UCB ECFCs  
We and others have successfully isolated human ECFC-derived EC colonies 
from low-density MNCs in umbilical cord blood by utilizing cEGM-2 medium (Au 
et al 2008a, Ingram et al 2004, Melero-Martin et al 2007). To evaluate whether 
SRM is able to promote ECFC outgrowth and proliferation, we compared these 
two culture media directly. MNCs from the same donor were divided into portions 
with half of them cultured in SRM and the rest in cEGM-2. The first ECFC 
colonies were detected after 4.35 ± 0.25 days in SRM, compared to 6.10 ± 0.38 
days in cEGM-2 (p < 0.001, Figure III.2A). No difference was observed in the 
frequency of ECFCs recovered on day 10 under these two conditions (Figure 
III.2B). Colonies in SRM displayed a cobblestone appearance with variations in 
colony size, which indicated their heterogeneous proliferative abilities (Figure 
III.2C) as previously reported (Ingram et al 2004). 
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Figure III.2 Isolation of human cord blood ECFC-derived EC colonies from 
UCB MNCs by using SRM. (A) Time of initial ECFC derived EC colonies 
emerged from MNCs after culture initiation in SRM and cEGM-2. Results 
represent the mean number of days before initial EC appearance ± SEM (n = 
23, *P < 0.001). (B) Number of ECFC-derived EC colonies outgrown per 107 
MNCs after 10 days of culture initiation in SRM and cEGM-2. Results represent 
the average number of EC colonies ± SEM (n = 23). (C) Representative 
photomicrographs of individual human ECFC-derived EC colonies from UCB in 
SRM. Scale bar represents 100 µm. 
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Phenotypic characterization of human UCB ECFCs  
The ECFC colonies expanded and formed an endothelial monolayer in both 
types of culture media conditions. Immunophenotyping of the endothelial 
monolayer (Figure III.3) revealed that ECs cultured in SRM expressed 
endothelial cell-surface antigens CD31, CD34, CD144, CD146, VEGFR1, 
VEGFR2 and VEGFR3, which was similar with those cultured in cGEM-2. 
However, the expression of cKIT (the receptor of SCF) and CXCR4 (the receptor 
of SDFα1) was higher in ECs in SRM than in cEGM-2. This observation can be 
the result of the addition of hSCF and hSDFα1 in the endothelial culture medium 
(Broudy et al 1994, Volin et al 1998). Most importantly, the EC colonies cultured 
in SRM did not express the hematopoietic cell surface antigens CD11b, CD14, 
CD45 or AC133, which indicates that the HCP-supplemented culture 
environment was devoid of hematopoietic cell contamination.  
89 
 
 
A  
B  
Figure III.3 Phenotypic analysis of human cord blood ECFC-derived ECs 
cultured in SRM. Immunophenotyping of EC from the cultured monolayer 
derived from human cord blood ECFC in SRM (A) and cEGM-2 (B) by 
fluorescence cytometry. Similar to cells grown in cEGM-2, the ECs cultured in 
SRM expressed CD31, CD34, CD144, CD146, Flt-1, Flk-1, Flt-4, and Nrp2 but 
not CD45, CD14, CD11b or AC133. Moreover, the expression of cKit and 
CXCR4 was detectable in ECs grown in SRM, but not in cEGM-2. 
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Clonogenic ability and genomic stability maintained in human UCB ECFCs 
A complete hierarchy of ECFC in human peripheral and UCB derived ECs, based 
on proliferative and clonogenic abilities, has been previously identified (Ingram et 
al 2004). To determine whether such a proliferative hierarchy was also present in 
the ECs cultured in SRM, a single-cell clonogenic assay was performed. After 
single cells were plated in culture, some cells didn’t divide; while other cells 
divided and formed colonies of different sizes comprised of varying cell numbers. 
The frequency of single cells undergoing division was similar between samples 
cultured in SRM and those in cEGM-2 (28.10 ± 21.04 vs 34.30 ± 20.89, 
respectively). Moreover, the entire hierarchy of ECFCs, composed of high 
proliferative (HPP)-, low proliferative (LPP)-ECFC, endothelial-cluster and non-
dividing mature ECs, was exhibited in ECs cultured in SRM (Figure III.4). 
 
FISH with probes specific to the centromeres of chromosome 17 and 
chromosome X was utilized to detect chromosomal stability in the ECFC 
progeny. In preliminary experiments, we found that sequential passage of ECFC 
in cEGM-2 resulted in a decrease of the frequency of the diploid (2n) karyotype 
and an increase of tetraploid (4n) and aneuploid karyotypes, which indicated that 
a high concentration of FBS may disturb the chromosome stability (Grimes BR, 
manuscript in preparation). Here we showed that 1.5% HCP-supplemented SRM 
better maintains genetic stability in ECFC progeny than cEGM-2 (Figure III.5). 
After 30 days of culturing, 85.45% of all cells grown on SRM retained their diploid 
karyotype, which was higher than cells grown in cEGM-2 (73.54%). Conversely, 
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the frequency of the tetraploid karyotype was noticeably higher in cEGM-2 (25%) 
than in SRM (7.27%). 
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Figure III.4 Quantitation of the clonogenic and proliferative potential of 
single ECs derived from human cord blood cultured in SRM. (A) The 
distribution of colony sizes, where colonies were derived from single ECs 
grown in individual wells after 14 days of culture. The complete hierarchy of 
ECFCs was present in ECs cultured in SRM; that is similar to those grown in 
cEGM-2. Inset chart is the percentage of single ECs dividing at least once after 
growing 14 days in culture. No statistical difference in this frequency was 
observed between cells grown in SRM and those in cEGM-2. (n = 5) (B) 
Representive photomicrographs of EC colonies with varied sizes derived from 
single ECs. Scale bar represents 100µm. 
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Figure III.5 Genomic stability in human cord blood ECFCs cultured in 
SRM. (A) Fluorescence in situ hybridization (FISH) analysis of ECs using 
centromere probes specific for the X chromosome (red) and chromosome 17 
(cyan). Nuclei are stained with DAPI (blue). Normal (diploid) female cells 
display two X chromosomes (red spots) and two chromosome 17s (cyan 
spots). Tetraploid female cells display four X chromosomes (4 red spots) and 
four chromosome 17s (4 cyan spots). (B) FISH analysis of > 200 ECs after 30 
days of culture initiation revealed a higher diploid content in cells grown in SRM 
than those in cEGM-2. Chromosomally aberrant cells (tetraploid) were 
detectable at a frequency up to 25% in cells cultured in cEGM-2. 
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In vivo formation of chimera blood vessels 
We (Yoder et al 2007) and others (Au et al 2008a, Au et al 2008b, Melero-Martin 
et al 2008, Melero-Martin et al 2007) have demonstrated that human UCB-
derived ECFCs possess the potential to form de novo blood vessels when 
suspended in a collagen-fibronectin matrix or Matrigel and implanted 
subcutaneously into immunodeficient mice. To test the in vivo vessel-forming 
ability of UCB ECFCs cultured in SRM, the same methods were employed. After 
14 days of carrying implants containing ECFC cultured in SRM or cEGM2, the 
mice were euthanized; the grafts were harvested, and analyzed for human or 
murine blood vessel formation.  
 
H&E staining revealed the formation of human microvessels perfused with 
murine red blood cells in the graft, indicating human vessel anastomoses with the 
surrounding murine vasculature (Figure III.6A). To further verify the human origin 
of these vessels, an immunohistochemistry study with a specific anti-human 
CD31 antibody was conducted and the results are shown on Figure III.6A. Thus, 
ECFC progeny cultured in SRM can also form functional human-murine chimeric 
vessels in a short-term xenograft model of blood vessel formation similar to 
cEGM2 media cultured cells. Quantification of human microvessels that carry 
murine erythrocytes (Figure III.6B) showed that there was no statistical difference 
between the implanted cells cultured in these two culture media (SRM vs CEGM-
2 is 28.48 ± 14.86 vs. 14.73 ± 6.69 vessels/mm2). Furthermore, the size 
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distribution of these functional microvessels formed by ECFC cultured in SRM 
was similar to those cultured in cEGM-2 (Figure III.6C). 
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Figure III.6 Human cord-blood-derived ECFC cultured in SRM 
demonstrate the potential to form functional microvessels in 
immunodeficient mice. (A) H&E staining indicates microvessel formation in 
collagen-fibronectin gel after 14 days of implantation in NOD/SCID mice. Anti-
human CD31 staining further confirms the human origin of these vessels. Scale 
bar represents 100 µm. (B) The number of vessels formed by human cord-
blood-derived ECFCs and perfused with murine red blood cells per mm2 in the 
gel after 14 days of implantation. (n=6) (C) The size distribution of the 
microvessels formed by human-cord-blood ECFCs. These data indicate that 
there is no difference in the vessel-forming abilities of ECs cultured in SRM 
versus those in cEGM-2.  
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Discussion 
We have demonstrated a novel method that, for the first time, allows us to 
efficiently isolate and expand human ECFCs in vitro with a low concentration of 
HCP (1.5%) with no bovine serum additives. In SRM, human ECFC colony yields 
remain quantitatively similar as those in cEGM-2. Cells display robust 
proliferative ability in vitro and vessel forming capacity in vivo. Most importantly, 
cells in SRM are noted proved to be more genomically stable than those cultured 
in cEGM-2 as indicated by FISH analysis.  
 
A recent study illustrated that human platelet lysate (HPL) can replace FBS for 
large-scale propagation of human ECFCs (Reinisch et al 2009). This study 
supported the idea that human blood products can maintain endothelial cell 
growth in vitro similar to the support provided to MSC (Bieback et al 2009, 
Schallmoser et al 2007, Schallmoser et al 2008). Human endothelial serum-free 
medium (SFM), the basal medium in this culture system, is commercially 
available and when supplemented with 20 ng/ml recombinant hbFGF and10 
ng/ml recombinant hEGF is reported by the manufacturer to support the isolation 
and long-term culture of human umbilical cord artery and vein endothelial cells 
(HUAECs and HUVECs) and human dermal microvascular endothelial cells 
(HMVECs) (Invitrogen manuals). However, that culture medium formulation did 
not support human cord blood ECFC outgrowth in our pilot assay. Consequently, 
we had to consider addition of other factors.  
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An increasing number of cytokines and chemokines have been demonstrated as 
displaying proangiogenic properties. Among them, bFGF, EGF, VEGF, SCF, 
SDF1 α and IL6 have been extensively studied for their effects on angiogenesis 
(Ahmed & Bicknell 2009, Coultas et al 2005, Fan et al 2008, Gerritsen et al 2003, 
Heidemann et al 2004, Murakami & Simons 2008, Piao et al 2009). Thus, we 
added these cytokines to the basal media separately or in combination to 
examine whether they could promote ECFC emergence from human low-density 
MNCs. We found a mixture of growth factors with added 1.5% HCP to maximally 
promoted ECFCs to emerge from MNCs and propagate (data not shown). 
 
While 1.5% HCP substituted for 10% FBS in our studies, we were unable to 
isolate and expand the ECFC in the absence of HCP. This indicates that some 
yet-unidentified factors reside in the cord blood plasma that are critical for 
endothelial cell survival and proliferation are still missing. Therefore, it is very 
important to attempt to define such components, as that will ultimately allow the 
establishment of a completely defined, serum-depleted culture system. 
Additionally, the molecular mechanisms underlying the interaction of these 
factors supporting ECs growth need to be further investigated, to help us fully 
understand the biology of ECs. 
 
Emerging research debates whether human serum is better for maintaining 
genomic stability than FBS. Some studies suggest that autologous serum may 
favor chromosomal stability as compared to FBS (Schallmoser et al 2008, 
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Shahdadfar et al 2005), while others indicate that chromosomal stability is 
independent of the serum source (Dahl et al 2008, Meza-Zepeda et al 2008). Our 
prior study (Grimes, BR manuscript in preparation) and current observation 
support the opinion that genomic stability of ECFC may be related to serum 
concentration instead of serum source. Our investigation illustrated that a high 
concentration of FBS (10%) led to a higher frequency of abnormal tetraploid and 
aneuploid forms in ECFCs during 30 days of tissue culture, compared to a low a 
concentration of FBS (2%) or HCP (1.5%)(Grimes, BR manuscript in 
preparation). One possible explanation for a serum effect on maintenance of 
chromosomal stability, is that a high concentration of serum speeds cell division 
and results in cytokinetic failure at binucleated intermediates, producing 
tetraploidy; or it contributes to chromosome segregation errors, increasing 
aneuploidy (John 1981, Lingle et al 2005, Shahdadfar et al 2005). Thus, serum-
replacement (like well-defined serum derived recombinant proteins and growth 
factors) supplemented or serum-depleted culture media may need to be 
established to safely culture cells for eventual human therapeutic interventions.  
 
As mentioned earlier, human arterial and venous ECs cultured in cEGM-2 
exhibited modified arterial and venous gene expression patterns compared to 
freshly isolated ECs. We examined arterial and venous gene expression profiles 
in cells cultured with SRM. Similarly, we found some genes were upregulated 
and some were downregulated even after 7 days of culture from initiation (Figure 
III.7). This indicates that ECs can express different gene patterns when plated in 
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vitro, which is not surprising. In vivo, vascular endothelial cells line the inner layer 
of blood vessels; they are stabilized by mural cells (pericytes and smooth muscle 
cells) and the extracellular matrix, and are exposed to various oxygen tension 
and hemodynamic forces. However, in vitro, they were placed on collagen I 
coated plates filled with cEGM-2/SRM and were cultured under static conditions, 
which are totally different from an in vivo microenvironment. Therefore, a big 
challenge in studying ECFCs is to develop a new strategy for expanding them, 
while minimizing any disturbances in their phenotypical and functional properties.  
 
Manipulating culture conditions to maintain undifferentiated status in embryonic 
stem cells, hematopoietic stem cells, neuronal stem cells, as well as MSC, has 
been extensively studied (Ludwig et al 2006, Mannello & Tonti 2007, Moon et al 
2006, Reynolds & Rietze 2005). In sharp contrast, such studies on ECFCs are 
scarcely found. This is partially due to the paucity of knowledge regarding how 
endothelial stem/progenitor cells differentiate to various lineages: arterial ECs, 
venous ECs and capillary ECs. However, such studies are necessary and 
important, as they can lay the foundation for new therapies for vascular 
disorders.  
 
In summary, we report here the development of a novel formula of endothelial 
cell culture medium that is free of FBS and is supplemented with 1.5% HCP for 
expansion of human cord blood ECFCs in vitro. In creating this medium, we have 
also demonstrated that ECFCs grown on this medium retain their phenotype and 
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function, as well as their proliferative and neoangiogenic properties. This work 
contributes to the development of a complete serum-free culture system for 
ECFCs that we and others (Reinisch & Strunk 2009) believe will be required for 
future use as a human cell therapeutic.   
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Figure III.7 The expression of arterial and venous specific genes in 
HUAECs and HUVECs is measured by quantitative PCR. (A) Compared to 
freshly isolated HUAECs (D0), the arterial gene expression pattern was modified 
in HUAECs plated in SRM for 7days (D7). (B) HUVECs cultured in SRM for 7 
days adopt a gene expression profile which was different from freshly isolated 
HUVECs. 
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CHAPTER IV 
Dose-dependent Effects of Vascular Endothelial Growth Factor165 (VEGF165) 
and Notch Ligand Delta like 1 (Dll1) on in vitro Differentiation of Human 
Cord Blood Derived Endothelial Colony Forming Cells (ECFCs) 
Introduction 
The vascular system is systematically organized into arteries, veins and 
capillaries. It has been believed that the endothelial cell (EC)-derived primary 
capillary plexus differentiates into arteries and veins due to the influence of 
hemodynamic forces. However, recent studies reveal that arterial and venous 
specification is at least partially governed by genetic factors. In murine embryos, 
arterial- and venous-specific molecular markers are detectable when the primary 
capillary plexus is formed, before circulation is established. Numerous molecules 
and signaling pathways have been described that participate in arteriovenous 
(AV) differentiation. Arterial endothelial cells express high levels of Notch1, 
Jagged1, Delta like ligand 4 (Dll4), EphrinB2 (EDNB2), Neuropilin 1 (Nrp1) and 
Hey2 (Duarte et al 2004, Krebs et al 2000, Lawson et al 2002, Shutter et al 2000, 
Villa et al 2001, Wang et al 1998, Zhong et al 2001). On the other hand, venous 
endothelial cells are characterized by high level expression of EphB4, Neuropilin 
2 (Nrp2), and COUP TFII (NR2F2) (Wang et al 1998, You et al 2005). 
 
The Notch signaling pathway is an evolutionarily conserved pathway that is 
involved in a variety of developmental processes. Notch family members and 
Notch ligands are expressed throughout early vascular development and later 
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restricted in arteries. The expression of Notch1, Notch4, Jagged2, Dll1 and Dll4 
are specifically expressed in arterial endothelium. The role of these molecules in 
arterial specification has been demonstrated during murine embryogenesis 
(Adams & Alitalo 2007, Alva & Iruela-Arispe 2004, Rossant & Howard 2002, 
Shawber & Kitajewski 2004, Siekmann et al 2008). VEGF is one of the most 
potent and ubiquitous vascular growth factors that affect many aspects of 
endothelial cell biology. Recently, VEGF-A has been found to interact with the 
activated Notch pathway to determine and maintain arterial endothelial cell fate. 
 
We have successfully isolated circulating ECFCs from human umbilical cord 
blood. Using single cell clonogenic assays and functional assays, a hierarchy of 
ECFCs has been identified (Ingram et al 2004). Human cord blood ECFCs form 
microvessels in immunodeficient mice after subcutaneous implantation in 
collagen-fibronectin gels (Yoder et al 2007). Thus, human ECFCs derived from 
cord blood display properties consistent with stem/progenitor cells for the 
endothelial lineage. However, whether these cells can be directly specified to an 
arterial or venous fate has so far not been addressed. We hypothesized that 
human cord blood derived ECFCs are not committed to either an arterial or 
venous fate and are able to be differentiated into arterial ECs when given 
appropriate stimuli. 
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Materials and Methods 
Media and supplements 
Human Endothelial Serum Free Medium (SFM; Invitrogen, Grand Island, NY) 
was supplemented with 20 ng/ml human recombinant basic fibroblast growth 
factor (hrbFGF) (Invitrogen), 10 ng/ml human recombinant epidermal growth 
factor (hrEGF) (R&D, Minneapolis, MN), 10 ng/ml vascular endothelial growth 
factor 165 (VEGF165) (R&D), 10 ng/ml VEGF121 (R&D), 10 ng/ml stem cell factor 
(SCF) (R&D), 5 ng/ml stromal cell derived 1alpha (SDF1α) (R&D), 10 ng/ml 
interleukin 6 (IL6) (R&D) and 1.5% human umbilical cord plasma (HCP), to 
create serum-reduced medium (SRM).  
 
Isolation and culture of human umbilical cord blood (UCB) derived ECFCs  
Human UCB samples (50-100 mL) were collected in heparin-coated syringes 
from healthy newborns (38-40 weeks gestation). The Institutional Review Board 
at Indiana University School of Medicine reviewed and approved this study with 
exempt IRB status. UCB was diluted 1:1 with DPBS (DPBS; Invitrogen) and 
overlaid onto Ficoll-Paque PLUS (GE Healthcare, Piscataway, NJ). Cells were 
centrifuged for 30 minutes at room temperature (RT) at 1500 rpm. Mononuclear 
cells (MNCs) were isolated and washed with DPBS. For outgrowth of ECFC 
colonies, MNCs were resuspended in SRM. 3 x 107 MNCs were seeded onto 
each well of 6-well tissue culture plates precoated with Type I rat-tail collagen 
(BD Biosciences; Bedford, MA) and cultured as described in Chapter III. ECFC 
colonies appeared around 4 days of culture and were identified as spindle-
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shaped in appearance. After approximately 10 days of culture, the ECFC-derived 
ECs were released from the culture dish by TrypLE™ Express (Gibco, Grand 
Island, NY) and replated onto 25 cm2 tissue culture flasks pre-coated with Type I 
rat-tail collagen for subsequent passage. Characterization of human UCB ECFC 
derived ECs was conducted using monoclonal antibodies and fluorescence-
activated cell sorter (FACS) analysis as described in Chapter III. 
 
Isolation and culture of human umbilical artery endothelial cells (HUAECs) 
and human umbilical vein endothelial cells (HUVECs) 
Human umbilical cords were obtained from healthy newborns (38-40 weeks 
gestation). The Institutional Review Board at the Indiana University School of 
Medicine reviewed and approved this study with exempt IRB status. In each 
cord, either an umbilical artery or umbilical vein was canalized, rinsed twice with 
DPBS supplied with 4.8 mM sodium pyruvate (Invitrogen), and then infused with 
100 µg/mL Liberase Blendzyme2 (Roche Applied Science, Indianapolis, IN ) and 
4.8 mM sodium pyruvate supplemented DPBS. After 14 minutes of incubation at 
37°C, detached ECs were eluted into a 50 mL Falcon tube and centrifuged at 
1300 rpm for 10 minutes. The cell pellet was resuspended and cells were 
washed with DPBS twice. The ECs were then stained with anti-human CD31 and 
CD45 antibodies (BD Biosciences Pharmingen, San Diego, CA) and were sorted 
in a BD FACSAria cell sorter (BD Biosciences) to isolate a CD31+CD45- 
population of purified ECs using morphologic phenotypic and functional validation 
as previously described (Ingram et al 2005b). 
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Immobilization of Delta1ext-IgG protein 
Delta1ext-IgG protein (the extracellular domain of Dll1 fused to the Fc domain of 
human IgG1) was provided by Dr. Irwin D. Bernstein (Fred Hutchinson Cancer 
Research Center, Seattle, WA) (Delaney et al 2005, Varnum-Finney et al 2003). 
Non-tissue culture-treated plates were coated with decreasing concentrations of 
Delta1ext-IgG (20, 10, 5, 2.5, 1.25, 0.625 and 0.3125 µg/mL) or the same 
concentration of human IgG (Sigma-Aldrich, St. Louis, MO), diluted in PBS 
together with 5 µg/mL fibronectin fragment CH-296 (Takara Shuzo, Otsu, Japan). 
The plates were incubated overnight at 4°C, washed with PBS 3 times, and 
further incubated with 2% bovine serum albumin (BAS) dissolved in PBS at 37°C 
for 1 hour. Thereafter, the plates were washed with PBS 3 times and ready for 
plating cells. 
 
In vitro arterial specification of human UCB derived ECFCs 
Early-passage (2-4) human cord blood ECFCs were cultured in SRM with 50 or 
100 µg/mL of rhVEGF165 , or plated in Delta1
ext-IgG coated non-tissue culture 
plates (as described above) with SRM for 14 days to induce an arterial EC 
phenotype. Media were changed every 2 days. 
 
RNA isolation and conventional/quantitative RT-PCR 
Total cellular RNA was extracted with an RNeasy Micro extraction kit (Qiagen, 
Valencia, CA) as described by the manufacturer. RT reactions were performed 
using an Omniscript RT Kit (Qiagen). Conventional PCR was conducted by using 
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Go Tap Flexi DNA Polymerase (Promega, Madison, WI) according to the 
manufacturer’s instructions. The primer sequences are shown in Table IV.1. 
 
Gene Forward Reverse Tm Product 
size (bp) 
DLL4 TATTGGGCACCAACTCCTTC 
 
ACATAGTGGCCGAAGTGGTC 
 
55 349 
NOTCH1 GGCCAGAACTGTGAGGAAAA 
 
GCAGTAGAAGGAGGCCACAC 
 
57 327 
NOTCH4 TCTCCCTCTCCATTGACACC 
 
TGGAAGCACTCGTTGACATC 
 
55 323 
HEY2 TGGGGAGCGAGAACAATTAC 
 
GCACTCTCGGAATCCTATGC 
 
55 329 
VEGFR1 AGTTTAAAAGGCACCCAGCA 
 
ACGAGCTCCCTTCCTTCAGT 
 
55 362 
VEGFR2 GAGGGACTTGGACTGGCTTT 
 
GATTTGAAATGGACCCGAGA 
 
55 302 
VEGFR3 TGAACATCACGGAGGAGTCA 
 
TCAGGCTTGTTGATGAATGG 
 
55 337 
NRP1 GAAAAATGCGAATGGCTGAT 
 
AATCCGGGGGACTTTATCAC 
 
53 335 
NRP2 CAAACACTGTGGGAACATCG 
 
TGTCCAGCCAATCGTACTTG 
 
55 338 
EFNB2 (C) TTATTTGCCCCAAAGTGGAC 
 
CCTGGTTGATCCAGCAGAAC 
 
55 347 
EPHB4 GAGCTGTGTGGCAATCAAGA 
 
ACTTTGCAGACGAGGTTGCT 
 
55 345 
COUPTFII AACACATCGAGTGCGTGGT 
 
CAGGTACGAGTGGCAGTTGA 
 
55 311 
PECAM1 GCAAAATGGGAAGAACCTGA 
 
ACAGTTGACCCTCACGATCC 
 
55 316 
VECAD TGGACAAGGACACTGGTGAA TCTTGCAGAGTGACCAGCAC 
 
55 382 
ACTB GCCAGCTCACCATGGATGAT GTCTCAAACATGATCTGGGTC 57 388 
Table IV.1: Primers used for conventional RT-PCR 
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The PCR cycle profile was 94°C for 5 minutes; 94°C for 30 seconds, 53 or 57°C 
(depending on the different primers) for 30 seconds, 72°C for 45 seconds, and 32 
cycles with a final 72°C for 7-minute. PCR products were added to wells in a 2% 
agarose/ethidium bromide gel and exposed to electophoresis current. Migrating 
bands were photographed under UV light.  
 
Quantitative PCR was performed using FastStart Universal SYBR Green Master 
2x (Rox) (Roche). Amplification was carried out in an ABI 7500 (Applied 
Biosystems, Foster City, CA), using its default program. The relative standard 
curve of each gene amplification was first generated to determine the 
amplification efficiency (Eff). ATP5B was used as a housekeeping gene 
expression reference. To compare gene expression levels among HUAEC, 
HUVEC and ECFCs, results were presented as the ratio of each gene to ATP5B 
expression. For rhVEGF165 or Delta1
ext-IgG induction, gene expression levels in 
non-treated cells at Day 0 were considered as controls. Results were expressed 
as a fold change (in logarithmic scale) in comparison to the control. The 
quantitative analysis was performed according to Pfaffl’s method (Pfaffl 2001). 
The primer sequences are shown in Table IV.2. 
 
Etarget: amplification efficiency of target gene 
Eref: amplification efficiency of reference gene 
ΔCt target (control-treated)= Ct target,control - 
Cttarget,treated 
ΔCt ref (control-treated)= Ct ref,control - Ct ref,treated 
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Gene Forwards Reverse Eff 
VEGFR1 GCTTCTGACCTGTGAAGCAA 
 
CTCGTGTTCAAGGGAGTGGT 
 
1.987 
 VEGFR2 GAACATTTGGGAAATCTCTTGC CGGAAGAACAATGTAGTCTTTGC 1.917 
VEGFR3 AGACAAGAAAGCGGCTTCAG TTGGGAGTCAGGGTGTGC 1.860 
 NRP1 GTTGTGTCTTCAGGGCCATT 
 
AATCCGGGGGACTTTATCAC 
 
2.036 
 NRP2 TCTGCGCTACGAGATCTTCA GTGCAGTCCAAGTTGTGTGG 1.862 
DLL4 GACCACTTCGGCCACTATGT TTGCTGCAGTAGCCATTCTG 1.967 
NOTCH1 CTTCAATGACCCCTGGAAGA 
 
GAAGTGGAAGGAGCTGTTGC 
 
1.950 
NOTCH4 CTGCTGCTGCTGCTATGTGT GTCAGGAAACTGGCACGTCT 1.833 
HES1 TGCTTCACTGTCATTTCCAGA 
 
GAAAGTCTGAGCCAGCTGAA 
 
1.958 
HEY2 CTTGTGCCAACTGCTTTTGA TCATGAAGTCCATGGCAAGA 1.912 
EFNB2 TCTTTGGAGGGCCTGGAT CCAGCAGAACTTGCATCTTG 1.986 
EPHB4 TTTGGCTCCTTCGAGCTG GGCCAAGATTTTCTTCTGGTG 1.880 
COUPTFII CCAAGAGCAAGTGGAGAAGC TCCACATGGGCTACATCAGA 1.988 
ATP5B CCACTACCAAGAAGGGATCTATCA GGGCAGGGTCAGTCAAGTC 1.960 
Table IV.2: Primers used for quantitative RT-PCR 
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Western Blot 
Protein extracts were prepared as described previously (Yang et al 2009), 
electrophoresed using sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (SDS-PAGE), transferred to nitrocellulose, and probed with anti-
human CoupTFII (R&D), anti-human Hes1 (Abcam, Cambridge, MA), anti-human 
Hey2 (Abcam) and anti-human β-actin (Abcam). All signals were detected by 
enhanced chemiluminescence. 
 
Implantation of human cord blood derived ECFCs into NOD/SCID mice  
Cellularized gel implants were cast as previously described (Yoder et al 2007). 
Cultured ECFCs (2.4 x 106 cells/mL) were suspended in a solution containing 1.5 
mg/mL rat-tail collagen I (BD Biosciences), 100 µg/mL human fibronectin 
(Chemicon), 1.5 mg/mL sodium bicarbonate (Sigma), 25 mM HEPES (Cambrex), 
10% FBS, 30%SFM, pH-adjusted to 7.4. Then 250 µL of the cell suspension was 
pipetted into one well of a 48-well tissue culture plate, allowed to polymerize at 
37°C for 30 minutes, and covered with 500 µL SRM for overnight incubation at 
37°C, in 5% CO2. Gels were implanted into the flanks of anesthetized 6- to 9-
week-old NOD/SCID mice. After 14 days, the mice were sacrificed; the grafts 
were excised and analyzed by histology and immunohistochemistry (n=6) as 
previously described (Yoder et al 2007). 
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Histology and Immunohistochemistry 
Zinc-fixed, paraffin-embedded tissue sections (6 µm) were deparaffinized and 
then either directly stained with hematoxylin and eosin (H&E) or immersed in a 
retrieval solution (Dako, Carpenteria, CA) for 20 minutes at 95°C to 99°C. Vector 
M.O.M. Immunodetection kit (Vector laboratories, Burlingame, CA) was then 
utilized according to the manufacturer’s instructions. Sections were stained for 
anti-human CD31 (clone JC70A, Abcam) and Cy3 conjugated anti-mouse 
smooth muscle α actin (αSMA) (clone 1A4, Sigma). Purified class- and species-
matched immunoglobulins (BD Pharmingen, San Jose, CA) were used for 
isotype controls. Sections were incubated with appropriate biotinylated 
secondary antibodies (Vector Laboratories, Burlingame, CA) and fluorescein 
streptavidin or streptavidin-horseradish peroxidase (HRP) (Vector laboratories), 
followed by development with 3,3-diaminobenzidine (DAB) solution (Vector 
laboratories). All the slides were mounted using 4’, 6-diamidino-2-phenylindole 
dihydrochloride (DAPI) (Molecular Probe, Eugene, OR) as a nuclear marker and 
then analyzed by visual inspection under 40x magnification. Images were 
acquired using a SPOT RT color camera (Diagnostic Instruments, Sterling 
Heights, MI) and analyzed using Metamorph 6.1 software (Universal Imaging 
System Corp, Westerchester, PA). 
 
Statistical Analysis 
Results are expressed as mean ± the standard error of the mean (SEM) for the 
study variables. Comparison of gene expression in the 3 types of ECs was 
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assessed by One-way ANOVA with a Tukey post test, performed using 
GraphPad InStat version 3.00 (GraphPad Software, La Jolla, CA). The change of 
gene expression after rhVEGF165 or Dll1 induction in ECFC were assessed by 
Student’s paired t-test. The vessel number and size distribution were evaluated 
by Students unpaired t test. A statistically significant difference was set at P < 
0.05.  
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Results 
Arterial and venous endothelial gene expression patterns are present in 
human cord-blood ECFCs 
Prior studies in chick, zebrafish and mice have suggested that many molecules 
are involved in arterial-venous determination during embryonic development 
(Table I.1). Moreover, global gene expression profiling revealed both arterial and 
venous gene expression patterns in cultured human vascular endothelial cells 
(Chi et al 2003). However, it is unknown to what extent these in vitro identified 
arterial and venous EC gene expression profiles reflect in vivo expression 
patterns. Thus, we directly evaluated gene expression in freshly isolated 
HUAECs and HUVECs.  
 
HUAECs and HUVECs were harvested from umbilical cords and successively 
sorted into a purified CD31+CD45- EC population (Figure IV.1A). Subsequently, 
cells were lysed and PCR was performed. As shown in Figure IV.1A, freshly 
isolated HUAECs and HUVECs displayed distinct arterial/venous EC gene 
expression patterns, which were consistent with published data (Chi et al 2003, 
Swift & Weinstein 2009). Dll4 and Notch4 were more abundant in HUAECs, but 
Notch1 predominated in HUVECs. For VEGF receptors, VEGFR2 (KDR) and 
NRP1 were expressed mainly in HUAECs, while VEGFR3 (FLT4) and NRP2 
mRNA were present in greater amounts in HUVECs. In particular, the important 
arterial EC gene marker Hey2 was predominately expressed in HUAECs; while 
the critical venous EC gene marker CoupTFII was enriched in HUVECs.  
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We next examined the expression of these genes in cultured human cord blood 
ECFCs. Of interest, ECFCs were able to exhibit both arterial and venous EC 
gene expression patterns, which were not weighted toward either an arterial or 
venous identity. Additionally, HUAECs, HUVECs and ECFCs displayed several 
typical EC surface markers such as PECAMI (CD31) and VE-Cadherin (VE-Cad), 
which confirmed their endothelial identity.  
 
We further quantified arterial and venous EC gene expression in HUAECs, 
HUVECs and ECFCs by utilizing qRT-PCR (Figure IV.1C). The expression of 
VEGFR2, Dll4, Notch4 and Hey2 was restricted in HUAECs, while NRP2 and 
CoupTFII were expressed preferentially in HUVECs. The transcriptional level of 
EprhinB2 was significantly higher in HUAECs than HUVECs; expression of 
EphB4 was higher in HUVECs than HUAECs. Therefore, in this study, Dll4, 
Notch4, Hey2 and EphrinB2 were assigned as arterial endothelial cell gene 
markers, and EphB4 and CoupTFII as venous endothelial cell gene markers. It is 
noteworthy that human cord blood ECFCs were able to express low levels of 
both arterial and venous endothelial cell gene markers, and thus are not 
committed in vitro to either an arterial or venous fate.  
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Figure IV.1 The expression of arterial and venous endothelial cell genes in 
freshly isolated HUAEC, HUVEC and human cord blood derived ECFCs. (A) 
Representative flow-cytometric analysis of freshly isolated HUAECs and 
HUVECs stained with isotype controls and monoclonal antibodies against human 
CD31 and CD45. The CD31+CD45- population was sorted as purified endothelial 
cells. (B) Distinct arterial and venous gene expression patterns are exhibited in 
freshly isolated HUAECs and HUVECs using conventional PCR. Human cord 
blood derived ECFCs present both arterial and venous gene expression profiles. 
Moreover, three types of cells all express endothelial-cell gene markers PECAM I 
and VE-Cadherin. (C) Quantitative PCR further confirms the distinct gene 
expression patterns in freshly isolated HUAECs and HUVECs. Human cord blood 
derived ECFCs are able to express both arterial and venous genes, suggesting 
the arterial or venous fate is not determined in this cell population. The mRNA 
levels in all panels are expressed in ratio to a housekeeping gene ATP5B. n = 5. 
*P < 0.05; **P < 0.01 and ***P < 0.001 by One-way ANOVA with a Tukey post 
test. 
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Dose-dependent and time-sensitive effects of rhVEGF165 on induction of 
an arterial endothelial gene expression pattern in human cord blood ECFCs 
VEGF is an important upstream factor that regulates arterial differentiation during 
embryogenesis and throughout life (Lawson et al 2002, Visconti et al 2002). We 
next determined whether rhVEGF165 is capable of inducing an arterial endothelial 
cell gene expression pattern in human cord blood ECFCs in vitro. Early passage 
(2-4) of pooled human cord blood ECFCs (n = 5) were cultured in the presence of 
rhVEGF165 over 14 days. Arterial and venous endothelial cell gene expression 
patterns were examined throughout the progression of stimulation by quantitative 
RT-PCR (data not shown). This revealed that the arterial endothelial cell gene 
marker EphrinB2 was significantly upregulated after 14 days of culture with 50 
ng/mL of rhVEGF165. In contrast, the venous endothelial cell gene markers Coup 
TFII and EphB4 were not significantly affected nor were expression of the other 
arterial endothelial cell gene markers Dll4, Notch4 and Hey2 (Figure IV.2). These 
observations suggest that an arterial endothelial cell gene expression profile is 
not completely induced under rhVEGF165 stimulation in vitro. 
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Figure IV.2: The alteration of arterial and venous endothelial cell gene 
expression in human cord-blood-derived ECFCs’ response to 14 days of 
rhVEGF165 stimulation. Q-RT-PCR analysis shows upregulation of expression 
of some arterial endothelial cell gene markers (VEGFR2, Dll4, Notch4,). IN 
particular, EphrinB2 mRNA significantly increases upon stimulation with 50 
µg/mL of rhVEGF165, while the mRNA expression of the venous gene marker 
CoupTFII decreases. Expression levels are presented as a fold change (in 
logarithmic scale) compared to baseline levels, which are normalized using 
ATP5B as a housekeeping gene. The expression at Day 0 in non-treated cells 
acts as baseline. n = 5. *P < 0.05 by paired Student’s t-test.  
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Dose-dependent and time-sensitive effects of Dll1 on induction of an 
arterial endothelial gene expression pattern in human cord blood ECFCs in 
vitro 
Developmental studies indicate that activation of Notch signaling is located 
downstream of VEGF stimulation and further drives an arterial endothelial cell 
gene expression pattern in endothelial cells. We decided to test whether an 
arterial endothelial cell gene expression pattern could be induced in human cord-
blood ECFCs directly via activated Notch signaling. In this study, the engineered 
Notch ligand, Delta1ext-IgG, consisting of the extracellular domain of Dll1 fused to 
the Fc portion of human IgG, was used to activate Notch signaling. An enzyme-
linked immunosorbent assay was utilized to confirm that the concentration of 
ligand coated on the tissue culture plate surface correlated with the amount of 
ligand bound as previously described (Delaney et al 2005). The linear 
relationship between the amount of immobilized ligand and activation of Notch 
signaling was measured by the expression of Notch downstream target genes 
Hes1 and Hey2 (Figure IV 3A and 3B). After 3 days of culturing, cells were 
harvested and the expression of Hes1 and Hey2 was examined by quantitative 
RT-PCR. Expression of Hes1 and Hey2 increased as the concentration of 
Delta1ext-IgG increased. This indicated that human cord blood derived ECFCs 
were capable of responding to Notch ligand Dll1 stimulation.  
 
We next evaluated whether Delta1ext-IgG influences arterial/venous endothelial cell 
gene expression patterns in human cord blood ECFCs. Early passaged (2-4) 
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pooled human cord blood ECFCs (n = 5) were cultured in wells coated with 
Delta1ext-IgG at concentrations ranging from 0.312 to 20 µg/mL, or with the same 
concentration of human IgG as the control ligand. ECFCs displayed a Delta1ext-
IgG dose-dependent increase in Hes1- and Hey2-mRNA expression over 14 days 
of culture (data not shown). It is noteworthy that the arterial endothelial cell gene 
markers Hey2 and EphrinB2 were significantly upregulated after 3 days of 
Delta1ext-IgG induction (10 µg/mL). In contrast, the expression of the venous 
endothelial cell gene markers CoupTFII and EphB4 were not significantly 
affected (Figure VI.3C). Consistently, the alteration of gene expression at the 
transcriptional level was confirmed at the translational level (Figure IV.3D). These 
results demonstrated that Notch ligand Dll1 was able to enhance the arterial 
endothelial cell gene marker expression in human cord blood ECFCs in vitro. 
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Figure IV.3 The alteration of arterial and venous endothelial cell gene 
expression in human cord blood derived ECFCs response to 3 days of 
Delta1ext-IgG induction. The dose-dependent activation of endogenous Notch 
signaling in human cord blood derived ECFCs is indicated by Hes1 (A) and Hey2 
(B) expression after 3 days of incubation in various concentrations of Delta1ext-IgG 
using quantitative PCR. (C) Q-RT-PCR analysis shows arterial endothelial cell 
gene markers Hey2 and EphrinB2 are significantly increased after 3 days of 
stimulation with 10 µg/mL Delta 1ext-IgG, whereas the expression of venous gene 
markers CoupTFII and EphB4 are not significantly affected. Expression levels 
are presented as a fold change (in logarithmic scale) compared to baseline levels 
and are normalized by using ATP5B as a housekeeping gene. The expression at 
day 0 in nontreated cells acts as baseline. n = 5. *P < 0.05 by paired Student’s t-
test. (D) Immunoblot analysis shows the protein level changes of Hes1, Hey2 
and CoupTFII are consistent with their mRNA levels of change. HUAEC is shown 
as the positive control for arterial EC, and HUVEC is the as positive control for 
venous EC.  
126 
 
Dll1-primed human cord blood ECFCs failed to enhance the formation of 
arteriole-like microvessels in vivo 
We further determined whether human cord blood ECFCs programmed to an 
arterial endothelial cell-like fate will form arteriole or arteriole-like vessels after 
they are implanted in vivo. ECFCs were cultured in a standard medium or treated 
with 10 µg/mL of Delta1ext-IgG for 3 days; then they were suspended in a collagen-
fibronectin matrix and subcutaneously transplanted into immunodeficient mice. 
After 14 days, the mice were euthanized; the grafts were harvested and analyzed 
for blood vessel formation. H&E staining and immunohistochemistry analysis 
using a specific anti-human CD31antibody revealed human cord blood ECFCs 
were able to form microvessels perfused with murine red blood cells in the graft 
(Figure IV.4A). Quantification of murine erythrocyte-containing human 
microvessels (Figure IV. 4B) showed no statistical difference between control 
and Delta1ext-IgG-treated cell implants (28.48 ± 14.86 vs. 36.37 ± 16.37 
vessels/mm2, respectively). Furthermore, the size distribution of these functional 
microvessels formed by treated and nontreated ECFCs were similar (Figure 
IV.4B).  
 
To further assess the formation of arterial-like microvessels, double-staining with 
anti-human CD31 and anti-mouse α smooth-muscle actin was conducted, as 
prior studies had demonstrated that human vessel recruitment of murine 
perivascular support cells in vivo (Enis et al 2005, Melero-Martin et al 2008, 
Melero-Martin et al 2007, Schechner et al 2000). Human ECFC-derived vessels 
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coated with murine αSMA-positive pericytes were indeed observed in the graft 
(Figure IV.4C). However, there was no statistical increase of such vessels in 
implants containing human cord blood ECFC primed with Delta1ext-IgG compared 
to control nontreated cells and HUAECs (data not shown). Together, these data 
indicate that in vitro Delta1ext-IgG-primed human cord blood ECFCs were unable to 
enhance arterial-like vessel formation in vivo, although they can be induced to 
express an arterial endothelial cell-like gene expression pattern in vitro. 
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Figure IV.4 in vitro Dll1 primed ECFCs fail to display significant skewing 
toward arterial EC phenotype and function in vivo upon implantation. (A) 
H&E staining indicates microvessel formation in collagen-fibronectin gel after 14 
days of implantation. Anti-human CD31 staining further confirms the human 
origin of these vessels. Results suggest that human cord blood derived ECFCs 
cultured in the presence of Delta 1ext-IgG retain vessel-forming ability in vivo. 
Moreover, the number of vessels formed by human cord blood derived ECFCs 
and perfused with murine red blood cells per mm2 in the gel demonstrate no 
observable difference between Delta 1ext-IgG treated and nontreated samples (B). 
In additions, the size distribution of both populations of microvessels is similar 
(C). (n = 6) (D) Vessels formed by human cord blood derived ECFCs are positive 
for anti-human CD31 staining (green). Murine αSMA specifically reacts with 
murine pericytes (red). Double-positive staining with human CD31 and murine 
αSMA (*) indicates recruitment and investment of murine mural cells to human 
ECFC-formed microvessels, thus representing an arterial EC property. However, 
in vitro Dll1-primed ECFCs don’t skew to display arterial EC properties when 
implanted in vivo; thus the number of double- positive staining vessels is not 
significantly increased compared to cells under standard culture conditions. 
Scale bar represents 100 µm. 
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Discussion 
Studies in chick, zebrafish and mice have revealed molecular distinctions 
between arterial and venous ECs, as well the signaling pathways underlying AV 
specification during development (Aitsebaomo et al 2008, Rocha & Adams 2009, 
Swift & Weinstein 2009). The most recent studies of murine embryonic stem cells 
(ESCs) (Lanner et al 2007, Yurugi-Kobayashi et al 2006), human multipotent 
adult progenitor cells (MAPCs) (Aranguren et al 2007) and human bone 
mesenchymal stem cell (MSCs) (Zhang et al 2008) have illustrated the potential 
of these stem cells to differentiate into cells displaying gene expression patterns 
similar to arterial and/or venous ECs. However, no reports to date have shown 
that human ECFCs are able to adopt an arterial or venous endothelial cell-like 
fate. Thus, this study is the first to demonstrate that human cord blood derived 
ECFCs heterogeneously express molecules that normally are restricted to 
arterial and venous endothelium. In vitro, exposure to Notch ligand Dll1 is 
sufficient to induce an arterial gene expression pattern in ECFCs. However, the 
in vitro Dll1-primed ECFCs, when implanted, failed to display significant skewing 
toward an arterial EC phenotype or function in vivo. Nonetheless, this study 
contributes to the understanding of possible mechanisms involved in AV 
differentiation in vitro and postnatal arteriogenesis in humans, which ultimately 
may provide potential new therapeutic strategies for human cardiovascular 
diseases.  
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Studies in zebrafish and mice have indicated that VEGF plays a critical role in 
determining AV specification and that the concentration of VEGF influences this 
determination. In murine ESCs, a high concentration of VEGF (50 ng/mL) drove 
arterial endothelial cell gene expression (Dll4, Notch4, Nrp1 and EphrinB2), while 
a low dosage of VEGF (2 ng/mL) encouraged venous endothelial cell gene 
expression (CoupTFII) (Lanner et al 2007). Similarly, 100 ng/mL of rhVEGF165 
could upregulate arterial endothelial cell gene marker expression in hMAPCs 
(Dll4, Hey2, EphrinB1 and EphrinB2) and in hMSCs (Dll4, Notch4 and EphrinB2) 
(Aranguren et al 2007, Zhang et al 2008). Our results consistently showed that 
VEGF at 50 ng/mL was sufficient to enhance expression of the arterial 
endothelial gene EphrinB2 only. Although the expression of Dll4 and Notch4 was 
increased, the change was not statistically significant. Likewise, upon VEGF 
stimulation, the expression of venous gene marker CoupTFII was downregulated 
but not significantly. These findings suggest that a high concentration of VEGF is 
able to induce the expression of at least one arterial endothelial cell gene in 
cultured human circulating ECFCs.  
 
Notch is another critical factor in determining and promoting vascular 
development. Mice with deficiencies in Dll4, Notch1, RBP-Jk and Hey1/2 lose 
expression of arterial endothelial cell gene markers (Duarte et al 2004, Fischer et 
al 2004, Kokubo et al 2005, Krebs et al 2004, Uyttendaele et al 2001). Dll1 
recently has been established as necessary for maintaining arterial identity 
during fetal development and mediating postnatal arteriogenesis in mice with 
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hindlimb ischemia (Limbourg et al 2007, Sorensen et al 2009). Dll1 expression in 
the vascular endothelium is detected in murine embryos at embryonic day 13.5 
(E13.5) in arteries but not in capillaries and veins. Dll1-mediated Notch activity 
via Notch1 is pivotal for controlling arterial identity during fetal development 
(Sorensen et al 2009). Similarly, Dll1-dependent Notch signaling is required for 
upregulation of EphrinB2 in growing arteries (Limbourg et al 2007). In this regard, 
the signaling cascade (Dll-Notch/Hey2/EphrinB2) responsible for determining 
arterial identity, which has been extensively studied in Dll4 (Aitsebaomo et al 
2008, Rocha & Adams 2009, Swift & Weinstein 2009), is now also present in 
Dll1. However, Dll1’s influence on arterial specification in human ECFCs has not 
yet been addressed. In this study, we showed that human ECFCs were 
responsive to Dll1 stimulation in a dosage-and time-dependent manner. After 3 
days of Dll1 induction (10 µg/mL), the expression of critical arterial gene markers 
(Hey2 and EphrinB2) were noticeably increased, which is consistent with prior 
studies of HUVECs where Dll4 and Notch4 were constitutively expressed 
(Shawber et al 2003, Williams et al 2006). On the other hand, venous endothelial 
cell gene markers (CoupTFII and EphB4) were not influenced under Dll1 
induction, which also has been observed when Notch4 or the Notch intracelluar 
domain (NCID) was overexpressed in HUVECs (Iso et al 2006, Shawber et al 
2003). Thus, these data illustrate that DII1 induction of arterial endothelial cell-
like gene expression is independent of suppression of the venous endothelial 
cell-like phenotype in human circulating ECFCs cultured ex vivo.  
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Although an arterial endothelial cell-like gene expression pattern was able to be 
induced in human circulating ECFCs in vitro upon Dll1 stimulation, these ECFCs 
failed to display significant skewing toward an arterial EC phenotype and arterial 
functions in vivo. A possible reason for this is that these cells were not 
continuously exposed to Dll1 stimulation. It had been reported that only 
immobilized Dll1 can activate Notch, and soluble Dll1 inhibits Notch (Varnum-
Finney et al 2000). Delta-1ext-IgG was not directly supplemented in the implanted 
collagen-fibronectin gel in this present study. To overcome this diffusion 
restriction, some carriers or scaffolds will need to be employed to immobilize Dll1 
in the gel in future studies. In this case, both the cell carrier and cell density 
should be determined to ensure that ligand-cell and cell-cell interfaces are 
interacting directly to induce Notch activation.  
  
It has been reported that Bcl2-transduced HUVECs suspended in a collagen-
fibronectin matrix and implanted under mouse abdominal skin were able to be 
remodeled into arterioles, venules and capillaries after 60 days (Enis et al 2005, 
Schechner et al 2000). Additionally, human ECs co-implanted with murine 
mesenchymal precursor cells 10T1/2 or human bone-marrow-derived MSCs 
were capable of giving rise to long-lasting, stable, engineered vessels and 
demonstrating distinct arterial and venous functional characteristics (Au et al 
2008a, Au et al 2008b). These findings suggest the potential of human ECs to be 
differentiated into functional arterial ECs in vivo, which is consistent with our 
short-term implantation outcomes. In the present study, anti-human CD31 and 
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anti-murine αSMA staining revealed that some human ECFC-formed vessels 
were covered with murine periendothelial mesenchymal cells, which indicated 
that human ECFCs adopt an arterial endothelial cell-like phenotype in vivo. 
However, there was no dramatic increase in recruitment and investment of mural 
cells to vessels derived from Dll1-primed ECFC compared to those formed by 
nontreated ECFC or HUAEC (data not shown). Addition of mural cells to the 
ECFC may be an additional strategy to provide Notch ligand exposure to the 
implanted human ECFC and progeny. 
 
In summary, we have demonstrated that human cord blood derived ECFCs are 
not committed to either an arterial or venous fate during in vitro culture but can 
be induced in vitro to display an arterial endothelial cell-like gene expression 
pattern after exposure to Notch ligand Dll1. However, in vitro Dll1-treated ECFCs 
fail to display significant skewing toward an arterial EC identity upon implantation, 
suggesting that in vitro priming is not sufficient for in vivo specification in our 
current experimental model. Our findings contribute to a greater understanding of 
the mechanisms underlying A/V differentiation in human ECFCs and may also 
provide novel insights into future therapeutic strategies for vascular regeneration 
in human subjects with vascular disease
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CHAPTER V 
Acute Myocardial Infarction in Swine Rapidly and Selectively Releases 
Highly Proliferative Endothelial Colony Forming Cells (ECFCs) into 
Circulation 
The following chapter represents a manuscript published in the journal Cell 
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Abstract 
Background: We have recently identified endothelial colony forming cells 
(ECFCs) in human blood and blood vessels and ECFC are elevated in patients 
with coronary artery disease. Since pigs are a favored model for studying 
myocardial ischemia, we questioned whether ECFCs also exist in swine and 
whether myocardial ischemia would alter the number of ECFC in circulation.  
 
Methods and Results: ECFCs were present in circulating blood and aortic 
endothelium of healthy pigs. In pigs with an acute myocardial infarction (AMI) 
(n=9), the number of circulating ECFC was markedly increased compared to 
sham control pigs (15  6 vs. 1  1 colonies/100cc blood, P < 0.05). Moreover, 
the percentage of circulating high proliferative potential-ECFCs (HPP-ECFCs) 
was significantly increased following AMI induction compared to sham control 
(38.4  5.8% vs. 0.4  0.4%, P < 0.05) and to baseline (38.4  5.8% vs. 2.4  
2.4%, P < 0.05) blood samples.  
 
Conclusions: This is the first study to report that ECFCs are present in blood 
and aorta in healthy pigs and that the number and distribution of circulating 
ECFCs is altered following AMI. Since circulating ECFC are also altered in 
human subjects with severe coronary artery disease, the pig model of AMI may 
be an excellent preclinical model to test the role of ECFC in the pathophysiology 
of AMI.
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Introduction 
In 1997, Asahara and colleagues described a cell population derived from human 
circulating CD34+ cells that could differentiate ex vivo into cells with endothelial 
cell-like characteristics (Asahara et al 1997). These cells were termed endothelial 
progenitor cells (EPCs). Subsequent evidence suggested that these cells are 
derived from bone marrow, circulate in peripheral blood, and play an important 
role in both postnatal vasculogenesis and vascular homeostasis (Asahara & 
Kawamoto 2004, Khakoo & Finkel 2005, Kubota et al 2003, Miyamoto et al 2004, 
Rafii & Lyden 2003). However, the characterization of EPCs remains 
controversial. Currently, human EPCs are defined as cells that express CD34, 
CD133, and vascular endothelial growth factor receptor 2 (VEGFR2; 
KDR)(Peichev et al 2000). Human EPCs and their progeny have also been 
shown to express the endothelial markers von Willebrand factor (vWF), platelet 
endothelial cell adhesion molecule-1 (CD31), and to ingest acetylated low-
density lipoprotein (LDL) and bind to Ulex europaeus agglutinin I (Ingram et al 
2005a). Efforts to accurately define EPCs have been complicated by the 
presence of circulating cells that have certain properties of endothelial cells, but 
have a monocytic origin, termed circulating angiogenic cells (CACs) (Rehman et 
al 2003), as well as mature circulating endothelial cells (CECs) (Blann et al 2005, 
Dignat-George & Sampol 2000). These latter cells express the S-endothelial 
antigen (CD146) but also express some of the same proteins as EPCs, such as 
CD31, VEGFR2 and vWF.   
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In humans, another population of EPCs, termed late outgrowth endothelial cells 
has been reported (Gulati et al 2003, Lin et al 2000). These are marrow-derived 
cells that display robust proliferative potential ex vivo. Recently, we have 
determined that the late outgrowth endothelial cells represent one subpopulation 
of circulating endothelial colony forming cells (ECFCs) (Ingram et al 2004). A 
complete hierarchy of ECFCs displaying varying levels of proliferative potential 
has been isolated and characterized in human umbilical and adult peripheral 
blood and as well as in a variety of blood vessels(Ingram et al 2005a, Ingram et 
al 2005b, Ingram et al 2004). The cord blood ECFCs express high levels of 
telomerase and contribute to new vessel formation when implanted in vivo 
(Yoder et al 2007).   
 
Several recent reports have demonstrated that increased circulating 
concentrations of various populations of EPCs are correlated with reduced risk 
for an adverse cardiovascular outcome (Chen et al 2004, Ding et al 2007, Eizawa 
et al 2004, Güven et al 2006, Hill et al 2003, Loomans et al 2004, Mutunga et al 
2001, Nadar et al 2005, Schmidt-Lucke et al 2005, Solovey et al 1997, Vasa et al 
2001, Wang et al 2005, Werner et al 2005). However, patients with severe 
coronary artery stenosis that are clinically selected for a revascularization 
procedure also display the highest concentration of circulating late outgrowth 
cells (Güven et al 2006), highlighting the linked questions whether the increase of 
these cells represents a direct response to the occurrence of ischemia and 
whether they play a risk-modulating role in the context of ischemia. Since pigs 
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are a favored species to examine the pathophysiology of coronary artery injury 
and acute myocardial ischemia (AMI), we questioned whether circulating ECFCs 
are present in the blood of healthy pigs and whether inducing an AMI would 
specifically alter the circulating concentration of ECFCs. 
 
We have determined that ECFCs are resident in the aortic endothelium of normal 
pigs and circulate in pig peripheral blood, however, the frequency of these 
circulating cells is extremely rare. The circulating ECFCs in healthy pigs display 
proliferative potential that is limited. In pigs that have been stressed by an 
induced AMI, however, ECFCs with high proliferative potential (HPP-ECFC) 
promptly emerge in the circulation. Thus, swine possess circulating ECFCs as do 
adult human subjects, and the onset of myocardial ischemia leading to infarction 
is accompanied by an increase in concentration of the ECFCs, with preferential 
mobilization of a highly proliferative subset.    
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Materials and Methods  
Blood sample collection 
Animal handing and care was performed under the recommendations of the 
National Institutes of Health (NIH) Guide for the Care and Use of Laboratory 
Animals. Yorkshire domestic pigs (25-35 Kg) of mixed gender were enrolled in 
this study. Study animals were sedated with IM Ketamine (20 mg/kg), and 
atropine (0.05 mg/kg), followed by IV sodium pentothal (25 mg/kg).  After 
intubation, anesthesia was maintained with Isoflurane (2.5%). Arterial access 
was obtained via the common carotid artery using a cutdown technique, and an 
8F vascular sheath was used to cannulate the artery. Left heart catheterization 
was performed using a hockey-stick catheter (Cordis) for coronary cannulation.  
A femoral artery sheath was placed to maintain continuous hemodynamic 
monitoring during the procedure. 
 
AMI was created by inflating an angioplasty balloon for 45 minutes in the 
proximal LAD artery immediately distal to the first septal perforator. All study 
animals received IV amiodarone to minimize ventricular arrhythmias; amiodarone 
dosage was 75 mg IV bolus over 10 minutes given just prior to balloon inflation, 
followed by 1 mg/min infusion continued for the duration between balloon 
inflation and deflation. Nevertheless, sustained ventricular tachycardia and 
ventricular fibrillation occurred during balloon inflation in every animal (2.9  1.6 
episodes/procedure) and was terminated using biphasic DC cardioversion 
(Medtronic). Peripheral blood was collected at baseline before AMI, 
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immediately post AMI and at sacrifice 7 days later (Figure V.1A). Sham control 
pigs underwent all operative preparation, catheter instrumentation, and three DC 
cardioversions but were not made ischemic (Figure V.1B). 
 142 
 
 
A 
 
B 
 
Figure V.1 Overview of experimental design. The circles indicate blood 
sampling times in the infarcted (A) and control sham pigs (B). 
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The extent of myocardial damage created by coronary occlusion was assessed 
by tetrazolium trichloride (TTC) staining of harvested hearts (7 days following 
AMI). TTC staining was performed using a standard protocol(Adegboyega et al 
1997). The hearts were taken immediately after sacrifice and were sliced into 5 
sections of 1.5-2.0 cm thickness along the apical-basal axis. These sections 
were immersed into TTC solution for 10 minutes at 37C. Afterwards, MI areas 
(pale areas not staining with TTC solution) were quantified by manual tracing 
using NIH imaging software and were expressed as a percentage of the total left 
ventricular area. The mean myocardial infarction was 26 ± 5% of the whole left 
ventricular area in this series of 9 pigs. This model results in a decrease in left 
ventricular ejection fraction approximating 46% (Hou et al 2005). 
 
Isolation and culture of porcine blood derived endothelial cells  
Blood (50-100ml) was diluted one to one with Hank’s/bovine serum albumin 
(BSA)/ethylenediamine tetraacetic acid (EDTA) solution and layered (2:1 ratio) 
onto Histopaque1119 (Sigma-Aldrich, St. Louis, MO). Cells were centrifuged for 
30 minutes at 1800 rpm at room temperature (Beckman Coulter, Allgera Tm 6R 
centrifuge). Mononuclear cells (MNCs) were isolated and washed three times 
with endothelial cell basal medium-2 (EBM-2) (Cambrex, Walkersville, MD) 
supplemented with 20% porcine plasma derived serum (PDS) (Animal 
Technologies Inc. Tyler, TX), 2% antibiotic-Antimycotic (Invitrogen, Grand Island, 
NY) (complete EGM-2 medium). MNCs were resuspended in 5 ml of complete 
EGM-2 medium and cells were plated onto a six well plate pre-coated with mg/ml 
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type I rat tail collagen (BD Biosciences, Bedford, MA) and incubated at 37°C, 5% 
CO2 in a humidified incubator. After 48 hours of culture, the non-adherent cells 
were removed and complete EGM-2 medium was added to each well. Medium 
was changed daily for the first seven days and then every other day until the first 
passage.  
 
Colonies of endothelial cells appeared in general following 7-14 days of culture 
and were identified by their cobblestone appearance. Endothelial colonies were 
enumerated by visual inspection with an inverted microscope (Olympus, Lake 
Success, NY). These ECFC-derived endothelial cells were released from the 
culture dish by 0.25% trypsin-EDTA (Gibco, Grand Island, NY) and replated onto 
25 cm2 tissue culture flasks pre-coated with type I rat tail collagen for subsequent  
passage. 
 
Isolation and culture of porcine aortic endothelial cells 
Endothelial cells were obtained from fresh aorta pieces by gently and thoroughly 
scraping the vessel wall with a disposal scraper (Fisher Scientific, Pittsburgh, 
PA). These cells were completely transferred from the edge of scraper into six 
well plates filled with complete EGM-2 medium and pre-coated with type I rat tail 
collagen. After 48 hours of culture, the non-adherent cells were removed and 
complete EGM-2 medium was added to each well. Medium was changed every 
other day until the first passage.  
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Endothelial colonies appeared on day 3 of culture and kept growing to form an 
endothelial monolayer with typical cobblestone appearance. These aortic ECFC- 
derived endothelial cells were released from the culture dish by 0.25% trypsin-
EDTA (Gibco, Grand Island, NY) and replated onto 25 cm2 tissue culture flasks 
pre-coated with type I rat tail collagen for future passage. 
 
Uptake of Dil-acetylated-low density lipoprotein (Dil-Ac-LDL) 
Early passage (2-4) ECFC-derived endothelial cells were incubated with 10 
µg/mL of Dil-Ac-LDL (Biomedical Technologies Inc., Stoughton, MA) in complete 
EGM-2 medium for 4 hours at 37°C. Cells were washed three times, stained with 
1.5µg/mL of 4’, 6-diamidino-2-phenylindole dihydrochloride (DAPI) (Sigma), and 
examined by inspection through an inverted fluorescence microscope (Zeiss, 
Thornwood, NY) at 32x magnification. 
 
RT-PCR for eNOS 
Total cellular RNA was extracted with TRIzol (Invitrogen, Grand Island, NY) in a 
single-step method. RT reactions were performed using a SuperScript  First-
Strand Synthesis system (Invitrogen, Grand Island, NY). PCR was performed 
using the PuReTaq Ready-To-Go PCR Beads (GE Healthcare UK Limited, UK) 
according to the manufacturer’s instructions. The primer sequences for pig eNOS 
included: forward, 5’- AGCGGCTGCATGACATTGAGA-3’; reverse, 5’- 
ATGTCCTCGTGATAGCGTTGCT-3’ with a 397 base pair expected band. The 
primer sequences for pig GAPDH included: forward, 5’-
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ACATCAAGAAGGTGGTGAAGCAGG-3’; reverse, 5’- 
CACCCTGTTGCTGTAGCCAAAT-3’ with a 201 base pair expected band. The 
PCR cycle was 94°C, 5 min; 94°C 30s, 57°C 30s, 72°C 1min, and 30 cycles with 
a final 72°C 7 min cycle. PCR products were added to wells in a 2% 
agarose/ethidium bromide gel, exposed to electophoresis current, and migrating 
bands photographed under UV light.  
 
Immunophenotyping of endothelial cells 
Early passage (2-4) ECFC-derived endothelial cells were stained with 
monoclonal antibodies including, mouse anti-rat/pig CD31 (RDI. Flanders, NJ), 
mouse anti-pig CD45 (SEROTEC, UK), mouse anti-pig pan tissue (BD 
Biosciences, Bedford, MA), mouse anti-pig SLA-DR (BD Biosciences, Bedford, 
MA), or mouse isotype control antibody for 30 minutes at 4°C, washed three 
times, and analyzed by fluorescence activated cell sorting (FACS) using a FACS 
Calibur flow cytometer (Becton Dickinson, San Diego, CA) as previously 
described (Ingram et al 2005a, Ingram et al 2005b, Ingram et al 2004, Yoder et al 
2007).  
 
Single cell assays 
For early passage (2-4) ECFC-derived endothelial cells, the FACS Vantage 
Sorter (Becton Dickinson) was used to place one cell per well into 96 well plates 
pre-coated with type I rat tail collagen in 200µl of complete EGM-2 medium.  
Cells were cultured at 37°C, 5% CO2 in a humidified incubator. Media was 
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changed every five days. After 14 days of culture, the cells were fixed with 4% 
paraformaldehyde (Sigma, St. Louis, MO) in phosphate-buffered saline for 4 
hours at room temperature, then washed twice, stained with 1.5 µg/ml DAPI, and 
examined for the growth of endothelial cells. Those wells containing two or more 
cells were identified as positive for proliferation under a fluorescent microscope 
at 10x magnification. Wells containing fewer than 50 cells, were counted by 
visual inspection with a fluorescent microscope at 10x magnification. For those 
wells with more than 50 cells, colonies were imaged and cell number quantified 
using an Image J 1.36v program (Wayne Rasband, NIH). 
 
Statistical Analysis 
Results are expressed as mean±SEM. Date were compared with nonparametric 
(Wilcoxon or Mann-Whitney) test and significant differences were set at the P < 
0.05 level. All analyses were performed using InStat 2.0 software.
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Results 
Characterization of porcine endothelial colony forming cells (ECFCs) 
We have previously reported that human peripheral blood and vessels contain a 
hierarchy of ECFCs (Ingram et al 2005a, Ingram et al 2005b, Ingram et al 2004). 
However, the existence of this ECFC hierarchy in porcine blood and vascular 
endothelium has not been demonstrated. To isolate ECFCs, we harvested swine 
peripheral blood MNCs and aortic endothelial cells. Both ECFC-derived 
endothelial cells (ECs) were able to form a monolayer with typical cobblestone 
morphology of ECs (Figure V.2A,B). Generally there were 4  2 colonies growing 
from 8.5 ± 4.0 x 108 blood MNCs of healthy swine (n = 12). The appearance of 
the first aortic EC colonies (3  0 days) was earlier than any colonies identified 
from PB (11  1 days); from our human studies, those colonies emerging early 
generally display higher proliferative potential (Ingram et al 2005a, Ingram et al 
2005b, Ingram et al 2004). The PB and aortic ECFC-derived cells ingested Dil-
labeled acetylated low-density lipoprotein (AcLDL) (Figure V.3A). Moreover, 
endothelial nitric oxide synthase (eNOS), an enzyme generally thought to be 
endothelial-specific, was expressed at the mRNA level in both aortic and PB 
ECFC- derived ECs using reverse transcription-polymerase chain reaction (RT-
PCR) (Figure V.3B). To evaluate whether these cells displayed cell surface 
proteins with an EC phenotype, we assayed the ECFC-derived ECs for the 
expression of EC and leukocyte surface markers. All the ECFC-derived cells 
showed positive immunostaining for anti-platelet endothelial adhesion cell 
adhesion molecule-1 (CD31) and anti-pan-tissue antibodies, but did not express 
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either the common leukocyte surface marker CD45 or the SLA-DR antigen 
(Figure V.3C). Accordingly, the cultured cells derived from pig aorta and 
peripheral blood ECFCs were confirmed to be endothelial cells by both 
phenotypic and functional properties. 
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 Control group (n=3) Experimental group (n=9) 
 Baseline  Instrumented Baseline Post MI Sacrifice 
MNCs (x108) 8.5±4.0 2.3±1.6 3.5±1.3 4.3±0.9 3.1±0.6 
ECFC 
Colony  
5±2 1±1 5±2 15±6 6±2 
Values are mean±SEM, Instrumented vs. Post MI, p < 0.05 
Table V.1 The number of MNC and ECFC colony in 100cc porcine blood 
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Figure V.2 The formation of porcine aortic and PB ECFC-derived 
endothelial colony. (A) Aortic ECFC-derived endothelial colony as it appeared 
on day 3, day 5, day 7 and day 10 of culture. (B) PB ECFC-derived endothelial 
colony from adherent MNCs emerged on day 8, day 10, day 12 and day 15 of 
culture. (10x magnification, scale bar represents 100µm) 
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Figure V.3 Phenotypic and functional analysis of both aortic and PB ECFC-
derived ECs. (A) Aortic and PB ECFC-derived ECs incorporated Dil-Ac-LDL 
(red) and also stained with DAPI (blue) (32x magnification, scale bar represents 
100m). (B) Expression of eNOS in aortic and PB ECFC-derived ECs by RT-
PCR. (C) Immunophenotyping of MNCs and cell monolayers derived from aortic 
and PB ECFC-derived ECs by fluorescence cytometry. Both aorta and PB 
derived ECs expressed CD31, and Pan-tissue but not CD45 or SLA-DR 
antigens.  
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Hierarchical organization of porcine ECFC proliferative potential 
Circulating EPCs have been reported to serve as a robust biomarker for 
predicting the severity and risk of adverse cardiovascular illnesses in human 
subjects (Hill et al 2003, Werner et al 2005). Though EPCs are heterogeneously 
defined, EPCs (including ECFCs) and CECs have been used as biomarkers. We 
recently developed a single cell colony-forming assay to quantitate the 
clonogenic potential of individual human EPCs (Ingram et al 2005a, Ingram et al 
2005b, Ingram et al 2004). Using this assay we tested whether there was a 
hierarchy of proliferative potential in ECFC present in porcine vascular 
endothelium and peripheral blood. As shown in Figure V.4A, 70.4  13.9% of 
single plated aortic ECFC-derived and 46.2  14.4% of PB ECFC-derived ECs 
divided at least once during 14 days of culture. The hierarchy of ECFC is 
comprised of colonies that may be further described by the total number of 
progeny produced during a 14 day culture. Thus, single cells that gave rise to a 
colony containing more than 2000 cells were called high proliferative potential-
endothelial colony forming cells (HPP-ECFC). Single cells that formed a colony 
containing 51 to 2000 cells were called low proliferative potential-endothelial 
colony forming cells (LPP-ECFC), whereas single cells that produced 2-50 cells 
were defined as endothelial cluster forming cells, and mature non-dividing 
endothelial cells retained no proliferative potential.  In healthy animals at 
baseline, both aorta and PB contained ECFC with the full complement of dividing 
and non-dividing cells. The majority of these ECFC-derived colonies contained 
less than 2000 cells, however approximately 10.3  3.5% of aortic ECFC and 1.0 
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 1.0% of PB ECFC were classified as HPP-ECFC (Figure V.4B-C).  
Photomicrographs of the size of the various endothelial colonies/clusters are 
shown in Figure V.4D. To determine if the HPP-ECFC-derived progeny 
possessed self-renewal ability (cells displaying the ability to give rise to colonies 
of similar or greater proliferative potential), we replated aortic and PB HPP-ECFC 
progeny in a single cell clonal assay. After replating, 39.6  7.0% of the clonal 
progeny of single aortic HPP-ECFC could give rise to all subsequent stages of 
endothelial progenitors in addition to forming secondary HPP-ECFC (Figure 
V.4E-F). Similarly, 23.9  2.4% of clonal progeny of single PB HPP-ECFC were 
able to form secondary colonies upon replating. (Figure V.4E, G). These colonies 
could be further replated to form tertiary colonies (data not shown). Only HPP-
ECFC retained the ability to self-renew into secondary colonies with retained 
HPP-ECFC activity, distinguishing this colony as functionally distinct from LPP-
ECFC or endothelial cluster forming cells. Thus, a hierarchy of endopoiesis was 
demonstrated to exist in porcine endothelial cells isolated from aorta and from 
circulating blood.   
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Figure V.4 Quantitation of the clonogenic and proliferative potential of 
single endothelial cells derived from aortic and PB ECFCs. (A) The 
percentage of single aortic and PB ECFC-derived ECs dividing at least once 
after 14 days culture. (B-C) The distribution of different size of colonies derived 
from single aortic (B) and PB (C) derived ECs in an individual well after 14 
days of culture. (D) Representative DAPI- stained (blue) photomicrographs 
(10x magnification, scale bar represents 100µm) of the different endothelial cell 
clusters (< 50 cells) and colonies (> 50 cells) derived from single ECs. (E) The 
percentage of single endothelial cells from primary aortic and blood HPP-
ECFCs that gave rise to secondary colonies after 14 days of culture. (F-G) The 
distribution of different sizes of secondary colonies derived from single 
endothelial cells, which in turn were derived from primary aortic (F) and blood 
(G) HPP-ECFCs. Results represent the average of at least three independent 
experiments from different animals. (n=5) 
 
 157 
 
Alteration of the distribution of ECFCs in a porcine model of acute 
myocardial ischemia (AMI) 
A variety of reports indicate that the concentration of EPCs and CECs changes in 
human subjects with acute cardiovascular injury and in those at risk for 
developing an adverse cardiovascular event (Chen et al 2004, Ding et al 2007, 
Eizawa et al 2004, Güven et al 2006, Hill et al 2003, Loomans et al 2004, 
Mutunga et al 2001, Nadar et al 2005, Schmidt-Lucke et al 2005, Solovey et al 
1997, Vasa et al 2001, Wang et al 2005, Werner et al 2005). To examine 
whether the distribution of ECFCs in the circulating blood was affected during a 
controlled ischemic cardiovascular stress, we isolated blood derived ECFCs from 
pigs undergoing an experimental AMI. The AMI was created by balloon catheter 
inflation in the left anterior descending coronary artery (LAD) for 45 minutes. We 
harvested blood samples (n=9) before AMI (baseline), following AMI (post AMI) 
and at sacrifice 7 days later (sacrificed). Additionally, sham control pigs were 
anaesthetized, instrumented, and experienced 3 cardioversion procedures, but 
the balloon was not inflated to induce myocardial injury. There was no statistical 
difference in the blood MNC cell count between the 2 groups at baseline, post 
infarction and sacrifice (Table V.1). However, the number of circulating ECFC 
was noticeably higher in post AMI samples than in sham control pig blood (15  6 
vs. 1  1 colonies/100cc blood, P < 0.05). Thus, AMI causes a significant 
increase in circulating ECFC in affected pigs. 
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Next, we questioned whether the distribution of ECFC proliferative potential 
would be altered following ischemia in these different test blood samples. There 
was no statistical difference in the percentage of single cells dividing at least 
once between the groups at baseline, post infarction and 7 days later (Figure 
V.5A-B). Strikingly, the percentage of single cells giving rise to colonies of more 
than 2000 cells (HPP-ECFCs) dramatically increased in the blood following AMI 
compared to the sham control blood samples (38.4  5.8% vs. 0.4  0.4%, P < 
0.05) (Figure V.5C) and also to baseline blood samples (38.4  5.8% vs. 2.4  
2.4%, P < 0.05) (Figure V.5D). On the other hand, the percentage of single cells 
that formed colonies containing 51-500 cells remarkably decreased following 
infarction compared to sham control samples (29.2  2.2% vs. 76.2  4.5%, P < 
0.05) (Figure V.5C). The percentage of endothelial clusters (endothelial colony 
with 2-50 cells) present in the blood after AMI was also reduced compared to 
baseline (Figure V.5D). Finally, the percentage of HPP-ECFC in the blood 
samples drawn 7 days after AMI remained 2-fold greater than that measured at 
baseline, but this trend did not reach significance. In contrast, the distribution of 
ECFC in sham control animals was not disturbed from baseline following 
instrumentation (Figure V.5E).  
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Figure V.5 Quantitation of the clonogenic and proliferative potential of 
single endothelial cells derived from PB ECFCs in the swine undergoing 
experimental AMI. (A-B) The percentage of single PB ECFC-derived ECs 
dividing at least once after 14 days culture in the sham control group (n=3) (A) 
and in the experimental group (n=5) (B) when isolated at the indicated 
timepoints. (C) The comparison of the distribution of different sized colonies 
from a single PB ECFC-derived ECs in an individual well after 14 days of 
culture between Post MI and sham control, each isolated at 45 min following 
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coronary cannulation (D-E). The harvest time-dependence of the distribution of 
different sized colonies from single PB ECFC-derived ECs are shown for 
individual wells in the experimental group (D) and in the control group (E). 
Observations were made after 14 days of culture. *P<0.05 by nonparametric 
(Wilcoxon or Mann-Whitney) test. 
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Discussion  
This is the first study to define a hierarchy of ECFCs circulating in the 
bloodstream or present in blood vessels in swine. Using a single cell clonogenic 
assay, ECFCs could be resolved based on their proliferative potential. Further, 
we find that the number and distribution of circulating ECFCs is altered in 
experimental pigs within 45 minutes following onset of AMI. 
 
Previously we reported a hierarchy of ECFCs exists in human blood and blood 
vessels (Ingram et al 2005a, Ingram et al 2005b, Ingram et al 2004). The ECFCs 
were present in higher frequency in human umbilical cord blood than in adult 
peripheral blood and the distribution of ECFCs was weighted toward more HPP-
ECFC in the cord blood samples. The human ECFCs displayed a variety of cell 
surface proteins previously identified on human blood vessel endothelium and 
formed blood vessels when implanted in collagen gels into immunodeficient mice 
(Yoder et al 2007). Thus, human ECFCs display properties consistent with 
stem/progenitor cells for the endothelial lineage. Using the same strategy, a 
hierarchy of ECFCs was identified in porcine circulating blood and blood vessels 
in the current study. 
 
Growing evidence suggests that changes in the number of EPCs and CECs 
correlate with the risk of developing certain human clinical disorders. A decrease 
in number or impaired function of EPCs has been observed in patients with 
diabetes, heart failure and coronary artery diseases (Chen et al 2004, Eizawa et 
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al 2004, Loomans et al 2004, Tepper et al 2002). Moreover, the number and 
function of EPCs inversely correlates with the occurrence of cardiovascular 
events and death from cardiovascular causes (Hill et al 2003, Schmidt-Lucke et 
al 2005, Vasa et al 2001, Werner et al 2005). Conversely, elevated numbers of 
CECs have been demonstrated in patients with a variety of clinical disorders 
such as sickle cell crisis, septic shock, acute myocardial infarction, acute 
ischemic stroke and coronary artery disease (Güven et al 2006, Mutunga et al 
2001, Nadar et al 2005, Solovey et al 1997, Wang et al 2005). Consistent with 
these findings, late outgrowth ECFCs are increased in the bloodstream of 
patients with severe coronary artery disease (Güven et al 2006). Based on these 
human clinical observations, we have hypothesized that the change in circulating 
ECFC count and/or distribution could also be a surrogate biological marker for 
vascular function and cumulative cardiovascular risk and be utilized to predict the 
outcomes of vascular diseases.  
 
In this study, the frequency of circulating ECFCs in the blood of normal swine 
was quite low at baseline, but quickly increased with the induction of cardiac 
injury. Additionally, our study, based on a single cell clonogenic assay, provides 
evidence that an AMI could affect the proliferative distribution of ECFCs, 
specifically stimulating more HPP-ECFC emergence in the circulating blood. 
These results suggest that an AMI induces either an acute release of the ECFC 
from the damaged area or release of a mobilizing molecule that recruits the HPP-
ECFC into the circulation. Of interest, Güven et al (Güven et al 2006) recently 
 163 
 
reported that the concentration of late outgrowth endothelial cells is increased in 
those patients with the most severe coronary artery disease, and those patients 
selected for a revascularization procedure displayed a significantly higher 
number of circulating late outgrowth endothelial colony forming cells than 
patients who did not require a revascularization procedure; the mechanisms 
underlying this finding are not yet known. Multiple growth factors and cytokines 
are known to be released in the setting of AMI or exercise-induced ischemia, but 
their significance for ECFC dynamics is not known. The establishment here of an 
animal model with the property of robust and predictable ECFC mobilization 
forms the background for future studies directed towards uncovering potential 
molecular mechanisms for this mobilization. A comparison of factors circulating 
at baseline and during ischemia, and selective manipulation of these factors 
should provide insight into these mechanisms as well as potential future 
therapeutic targets.  
 
Endothelial cell proliferation in normal, mature vessels in most mammals is 
reported to be extremely low. In some experimental animals, such as rats, guinea 
pigs and dogs tritiated thymidine labeling studies demonstrated that 0.1-3.0% of 
endothelial cells proliferate daily (Caplan & Schwartz 1973, Schwartz & Benditt 
1973, Schwartz & Benditt 1976). In contrast to this slow turnover of endothelial 
cells in normal vessels, in vitro plating of swine aortic endothelial cells was 
associated with rapid proliferation, a finding consistent with numerous studies 
using human or bovine vessel-derived endothelial cells (Bompais et al 2004, 
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Cajero-Juarez et al 2002, Ingram et al 2005b, Ryan et al 1978). Furthermore, a 
complete hierarchy of ECFCs was present in the porcine vessel wall-derived 
endothelial cells, similar to that observed in circulating blood and consistent with 
that published for human blood and blood vessel-derived endothelial cells 
(Ingram et al 2005a, Ingram et al 2005b, Ingram et al 2004). These data suggest 
that some of the endothelial cells residing in the blood vessel intimal layer under 
normal circumstances are quiescent but retain proliferative potential that is 
displayed upon releasing the cells from contact inhibition and plating the cells in 
vitro. Future studies will be required to determine whether the source of inducible 
ECFC mobilization in porcine and human subjects is derived from the vascular 
endothelial intima of the host vessels or from extravascular marrow niches. 
 
In this study we compared the expression of a number of cell surface antigens in 
porcine hematopoietic MNCs and aortic and blood ECFC-derived ECs. Both 
types of endothelial cells showed similar expression pattern of these surface 
proteins, which was different from that of blood MNCs (Figure V.3C). 
Interestingly, these porcine ECFC-derived ECs expressed some surface antigens 
that were reported to be present in hematopoietic cells, such as the pan-tissue 
marker (granulocytes, monocytes and lymphocytes), whereas the common 
leukocyte surface marker CD45 and SLA-DR were not detected. Available 
evidence suggests that during embryonic development the hematopoietic stem 
cells (HSCs) and EPCs are derived from a common precursor, the 
hemangioblast, and then differentiate into different lineages and play distinct 
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functions (Baron 2003, Cogle & Scott 2004). This fact has led some investigators 
to postulate that circulating blood cells isolated from human and murine bone 
marrow transplant recipients or following development of leukemia provide 
evidence of a hemangioblast precursor for the hematopoietic and endothelial 
lineages in these adult subjects. Other than the pan-tissue marker, we saw no 
other evidence of cell surface antigen co-expression of markers between the 
hematopoietic and ECFC in this study. 
 
In conclusion, we report that ECFCs are present in normal circulating swine 
blood and comprise a proportion of the endothelial cells that represent the aortic 
endothelial intima. Though the circulating ECFCs are rare, some of these cells 
possess remarkable proliferative potential, also displayed by some of the ECFCs 
that reside as aortic endothelial cells. The onset of acute myocardial ischemia 
leads to prompt changes in circulating ECFC number and the selective 
mobilization of highly proliferative subpopulations. Identification of populations of 
circulating and resident vascular endothelial cells with such potent proliferative 
potential may improve our understanding of the cellular mechanisms of 
angiogenesis and permit new strategies to manipulate these cells to protect the 
vascular endothelium from injury and disease.
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CHAPTER VI 
Summary and Perspectives 
Circulating EPCs have been identified for more than a decade and have been 
indicated to contribute to neovascularization via postnatal vasculogenesis. 
However, the definition of an EPC remains controversial. Our lab has 
successively isolated and identified ECFCs in circulating blood and blood vessels 
in human and other species. Based on the strictest definition of an EPC as a cell 
that 1) displays the ability to produce endothelial progeny that form endothelial 
tubes in vitro and 2) contributes to the functional endothelial lining of injured 
vascular structure via angiogenesis and/or vasculogenesis in vivo, to date, only 
ECFCs fit the definition of true EPCs and display all the activities described on 
these chapters. Furthermore, we have extended this definition and identified the 
stem/progenitor cells for the corneal endothelial lineage. 
 
Corneal endothelium is formed by migration and proliferation of neural crest-
derived mesenchymal cells and plays a barrier-bump function to maintain corneal 
clarity. Unfortunately, corneal ECs fail to proliferate in vivo even in response to 
corneal trauma or diseases which causes cell loss and eventually leads to the 
loss of vision. However, they do display replicative capacity in vitro. In the 
present study, using a single-cell clonogenic assay, we are able to first 
demonstrate that not all corneal ECs display the same ability to proliferate at a 
clonal level. We have defined a hierarchy of ECFCs in bovine corneal 
endothelium based on their proliferative potential, which is quite similar to bovine 
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vascular ECs resident in aorta, coronary artery, and pulmonary artery and is 
consistent with circulating and resident vascular ECs in adult human subjects. 
Thus, this study provides a new conceptual framework for defining corneal EPC 
potential and contributes to identify corneal endothelial precursor which is 
currently controversial. Additionally, HPP-ECFCs in corneal endothelium with 
their vast proliferative potential may represent a novel cell source for 
reconstituting corneal endothelium and be of great benefit to corneal 
transplantation. 
 
Although human cord blood derived ECFCs are able to de novo form vessels, 
molecular mechanisms underlying the roles of ECFCs in neoangiogensis remain 
largely unknown. Several fundamental biological questions on EPCs’ mobilization, 
homing, differentiation, lumenization and more are pending answered. One of 
them that whether circulating ECFCs can be specified to an arterial or venous 
fate has so far not been addressed. Thus, we hypothesized that human cord 
blood derived ECFCs are not committed to either an arterial or venous fate and 
are able to be differentiated into arterial ECs when given appropriate stimuli. In 
the present study, we first demonstrate that human cord blood derived ECFCs 
heterogeneously express molecules that normally are restricted to ECs resident 
in arteries and veins. In vitro, exposure to Notch ligand Dll1 is sufficient to induce 
an arterial gene expression pattern in ECFCs. However, the in vitro Dll1-primed 
ECFCs, when implanted, failed to display significant weighting toward an arterial 
EC phenotype or function in vivo. Therefore, the in vivo formation of human cord 
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blood ECFCs derived, long-lasting, functional vessels with an arterial identity 
needs further investigated probably by manipulating implant microenvironments. 
Nevertheless, this study contributes to the understanding of possible 
mechanisms involved in AV differentiation in vitro and postnatal arteriogenesis in 
humans and provides novel insights into the development of cellular therapeutic 
strategies for patients with coronary and peripheral arterial diseases. 
 
There is growing evidence suggesting that the concentration of circulating ECs is 
close related to the adverse progression of cardiovascular disorders. Based on 
human clinical observations, we hypothesized that the alteration in circulating 
ECFC count and/or proliferative distribution could be a surrogate biological 
marker for vascular function and cumulative cardiovascular risk and be utilized to 
predict the outcomes of vascular diseases. Pigs are a favored species to 
examine the pathophysiology of coronary artery injury and acute myocardial 
ischemia (AMI). By using this animal model, we have demonstrated that the 
number of circulating ECFCs in the bloodstream in healthy swine is quite rare. 
The onset of AMI leads to a prompt increase in circulating ECFC number and a 
selective mobilization of HPP-ECFCs. The exact role of the mobilized HPP-
ECFCs in homing and participation in repair of the ischemic tissue remains 
unknown. Moreover, multiple growth factors and cytokines have been known to 
be released in the setting of AMI. Future, a comparison of factors circulating 
before, during and after ischemia, and selective manipulation of these factors 
would provide insights into these uncovering potential molecular mechanisms for 
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the mobilization of HPP-ECFCs. The identification and characterization of HPP-
ECFC may improve our understanding of the cellular mechanisms of 
neoangiogenesis and permit new strategies to manipulate these cells to protect 
the vascular endothelium from injury and disease. 
 
Based on their multiple therapeutic potentials, human ECFCs have become an 
attractive target for novel vascular regenerative therapies. However, the study of 
ECFCs is hampered by several challenges in culturing cells. Current protocols for 
in vitro expansion of ECFCs mostly depend on the presence of FBS or FCS in 
the culture medium which may disturb chromosome stability, modify gene 
expression and thereafter affect cell properties and functions, and have risky 
potentials of transmitting infectious agents and inducing immune reactions when 
future used in a transplantation setting. According to these regards, we have 
developed a novel formula of endothelial cell culture medium that is free of FBS 
and is supplemented with 1.5% HCP for expansion of human cord blood ECFCs 
in vitro. In creating this medium, we have also demonstrated that ECFCs grown 
on this medium retain their phenotype and function, as well as their proliferative 
and neoangiogenic properties. This work contributes to the development of a 
complete serum-free culture system for ECFCs that we and others believe will be 
required for future use in human cell therapeutics. 
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In summary, these studies contribute to an improved understanding of ECFCs 
and their roles in postnatal vascularization and suggest several possible 
therapeutic applications of ECFCs.  
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